



## **PRWeb: Technology Biotechnology**





*PRWeb® has offered free online press release distribution services since August 1997. Since then PRWeb® has gradually made the transition to a fully integrated press release newswire service. We are the largest Newswire catering to small and medium sized companies and organizations and one of the largest online press release newswires.*

*Our editors review thousands of press releases each week for distribution through the PRWeb® Newswire services.*

*As innovators and the acknowledged leader in online press release distribution since 1997, PRWeb has provided a simple, easy to use platform to ensure you get your message to the media and the masses. PRWeb has changed the way businesses, marketing departments and public relations firms think about press releases. Once a tool used exclusively for communicating with the media, PRWeb was the first company to develop a distribution strategy around direct-to-consumer communication.*

*A partial list of industry innovations include:*

- \* First free online press release distribution engine*
- \* First in search engine optimized (SEO) press release formatting*
- \* First in direct-to-consumer distribution of press release content*
- \* Fully-integrated press content (press release and attachments) in a search-engine friendly format*
- \* First free, search-engine optimized photowire*
- \* First to provide RSS-enabled press releases for easy syndication*
- \* Only press release distribution engine to provide TrackBacks for social commentary from blogs & websites*
- \* First with news and search engine friendly embedded links*
- \* Strategic partnerships with online partners who position your press release content at the forefront of the markets you aim to penetrate*
- \* Exclusive "Fair Commerce" contribution system provides worldwide distribution of your PR for a fraction of the traditional costs*
- \* Developed from the ground up as the most search engine optimized press release and content distribution platform in the world*

*Take PRWeb® for a Test-Drive Today.*

*All press release newswires talk a good game - but we'd like to prove to you how effective PRWeb® will be to your online visibility goals. Whether you're a Fortune 500 firm or a single person startup, PRWeb will provide you the platform, tools, instruction and personal support to start, build and manage your PR Campaign. Please email or give us a call and one of our friendly editors will help you get started. Whether you want to dominate your market or just make a little noise, PRWeb is here to help you thrive in the marketplace, and with the media. If you are a public relations firm new to PRWeb, we have a special program for you. Please call Joe Beaulaurier (360-312-0892 ext. 3617) to learn if you qualify for a risk-free introduction to the PRWeb platform.*

## National Insurance Carriers Now Cover Artificial Cervical Disc Surgery

*Insurance carriers across the country cover artificial disc replacement surgery for the cervical spine with greater frequency. The alternative to the more popular spinal fusion is gaining ground with 200,000 Americans with spinal disorders now having potential access to artificial disc surgery through insurers. The Chicago Institute of Neurosurgery and Neuroresearch (CINN) offers cervical artificial disc surgery from some of the most well-trained neurosurgeons in the country.*

Chicago, IL (PRWEB) July 13, 2009 -- For more than a decade, Virginia Sabine endured. But the vibrant 40-year-old wanted more than unbearable neck pain and addictive medication. She wanted her life back.

In 1996, Virginia had two discs fused. Now a third disc was acting up, and she went hunting for answers. She found them in Geoff Dixon, M.D., an experienced neurosurgeon with the [Chicago Institute of Neurosurgery and Neuroresearch \(CINN\)](#). He recommended an artificial disc for the cervical (neck) region that was [unanimously approved by the Food and Drug Administration in July 2007](#). Neurosurgeons at CINN are among the most well-trained surgeons in the country in performing cervical artificial disc surgery and frequently are asked to teach other spine surgeons in the technique.

"The decision to go with artificial disc replacement was easy," Virginia says. "Not only was the procedure covered by insurance, but the benefits far outweighed spinal fusion."

She says that the difference between the artificial disc operation and the fusion was night and day. "In 1996, I was in the hospital for five days and in a neck brace for two months. This time, I was out of the hospital and walking immediately, and the pain was completely gone within four days."

U.S. health insurers, too, see the same benefits in artificial cervical disc surgery that Virginia did. As a result, today they are extending coverage to a broad base of customers.

Now 200,000 Americans with spinal disorders have potential access through insurers such as Aetna, various BlueCross BlueShield plans and Broadspire to artificial disc surgery instead of the conventional cervical spinal fusion surgery. Other insurance carriers may approve the innovative procedure on a case-by-case basis. (A complete list of [insurance companies with positive coverage decisions for the cervical artificial disc](#) as of April 2009 can be found on the CINN website.)

Currently, the most common surgical treatment for patients with [degenerative discs in the cervical spine](#) is spinal fusion. In this procedure, a surgeon removes the damaged disc, then implants a bone graft and metal plate to fuse the vertebrae together. Challenges of spinal fusion include longer recovery time, pain management and the possibility of adjacent-level surgery in the future.

During [artificial disc replacement surgery](#), the damaged disc is removed and replaced with an artificial disc, a

stainless-steel device with a ball-in-trough design intended to allow for replication of normal motion. The disc stays in place with bone screws. The hospital stay for this procedure is approximately one to two days. Patients can begin rehabilitation and return to daily activities soon after surgery. In fact, one study demonstrated that patients receiving the cervical disc returned to work in 45 days, 16 days earlier than the fusion patients.

"Studies show that artificial cervical disc patients have a higher rate of neurological success as measured by muscle tone, strength, sensation, as well as responsiveness of reflexes as compared to those who've had spinal fusion," says Dr. Dixon. "Studies also demonstrate that at a two-year follow-up exam, the overall success rate for the artificial disc group is 79.3% compared to the fusion group at 67.8%. These reasons are compelling enough for potential candidates to consider the option of an artificial disc."

About CINN:

[The Chicago Institute of Neurosurgery and Neuroresearch](http://www.cinn.org) is one of the nation's leading organizations for the diagnosis, treatment and rehabilitation of people with brain and spine disorders. Founded in 1987, CINN is one of the Midwest's largest teams of neurosurgeons, physiatrists and neurologists known for their pioneering treatments in minimally invasive techniques. Through a network of seven hospitals throughout Chicagoland, CINN is a market leader in treating brain tumors and spine disorders.

For details on the cervical artificial disc, call: 1-800-446-1234 or visit <http://www.cinn.org>.

In addition to national carriers, many statewide carriers now cover artificial cervical (neck) disc surgery. Those insurers operate in: Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida, Hawaii, Indiana, Idaho, Illinois, Iowa, Louisiana, Michigan, Missouri, Montana, New Jersey, Minnesota, Nebraska, New York, New Mexico, Nevada, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Texas, Utah, Washington, Wyoming, Virginia and West Virginia.

###



### **Contact Information**

**Lisa Stafford**

Chicago Institute of Neurosurgery and Neuroresearch

<http://www.cinn.org>

630-986-8749

### **Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **Progenitor Cell Therapy Appoints VP of Manufacturing Operations**

### *PCT Recruits Experienced Pharmaceutical Production Executive to Head its Two U.S. Contract Manufacturing Facilities*

Hackensack, NJ (Vocus) July 13, 2009 -- Progenitor Cell Therapy, LLC (PCT) today announced the recent appointment of [Daryl LeSueur](#) as Vice President of Manufacturing Operations. As head of Manufacturing Operations, Daryl is responsible for managing and supervising the day-to-day conduct of the manufacturing, packaging, and operational functions of PCT's two North American contract manufacturing facilities.

Daryl brings to PCT over 25 years of experience in manufacturing operations in FDA-regulated industries. His experience includes proven leadership and success in developing and implementing operational initiatives to promote quality, reduce production costs, increase profitability and enhance operational efficiencies.

Prior to joining PCT, Daryl served as Vice President, Operations, Pomona, East Hanover and Northvale for Barr Laboratories. Before joining Barr, Daryl served as Vice President of Pharmaceutical Production at Novartis Pharmaceutical Corporation. At Novartis, he was responsible for managing all North American production operations, specializing in solid dosage, raw material and transdermal systems, and oversaw a \$70 million budget. Prior to Novartis, Daryl was Associate Director of Pharmaceutical Production with Sandoz Pharmaceutical Company.

Daryl has a B.S. in Chemistry from the State University of New York at Plattsburgh and has completed the Leadership Program, Finance Program, and Management Program at Harvard Business School.

“We are very pleased to add someone with the caliber of Daryl’s experience to our senior management team,” states PCT Chief Executive Officer, Dr. Andrew L. Pecora. “Bringing on seasoned executives who can ensure the highest quality service to our customers and execute our growth strategy is a critical component of our strategic plan”.

“Daryl’s experience with highly regulated pharmaceutical-grade production environments is a critical skill set to our commercial-quality service offering and is the kind of cross-sector recruitment that will be important to continue as regenerative medicine matures into a commercial sector”, adds PCT President and Chief Scientific Officer, Dr. Robert A. Preti.

#### About Progenitor Cell Therapy, LLC

Progenitor Cell Therapy, LLC (PCT) is a client-based company providing [cell therapy service solutions](#) for the research, development, manufacturing, and commercialization of cell-based therapies. With its cell therapy manufacturing facilities and team of experienced professionals, PCT provides current Good Manufacturing Practices (cGMP)-compliant services for pre-clinical and clinical development, manufacturing, and eventual commercialization of cellular therapies for clients throughout the world. For more information, please visit [www.progenitorcelltherapy.com](http://www.progenitorcelltherapy.com).

#### Disclaimer



This press release does not constitute an offer to sell, or a solicitation of any offer to buy any securities of Progenitor Cell Therapy. In addition, certain of the statements in this press release are forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, new products, research, and development activities and similar matters. These statements involve known and unknown risks, uncertainties, and other factors that may cause the company or its industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "intend," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue" or the negative of such terms or other comparable terminology. Forward-looking statements are only predictions. Actual events or results may differ materially. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance, or achievements. Moreover, neither the company nor any other person assumes responsibility for the accuracy and completeness of such statements. The company is under no duty to update any of the forward-looking statements after the date of this press release to conform such statements to actual results.

###



### Contact Information

**John P. Gandolfo**

Progenitor Cell Therapy, LLC

<http://www.progenitorcelltherapy.com>

(201) 883-5316

### Online Web 2.0 Version

You can read the online version of this press release [here](#).

### News Image





## **Salugen AG (SYMBOL: SQZ.F) Successfully Conducts Frankfurt Stock Exchange Listing**

*Salugen shares rise over 70 percent in the first month as the first publicly-traded nutrigenomics company is listed on the FWB® Frankfurter Wertpapierbörse (the Frankfurt Stock Exchange)*

Zurich, Switzerland and San Diego, CA USA (PRWEB) July 13, 2009 -- Salugen® AG ([www.salugen.com](http://www.salugen.com)), a life sciences company, announces the successful listing of its stock traded on the FWB® Frankfurter Wertpapierbörse (the Frankfurt Stock Exchange) under the symbol SQZ (FRA:SQZ.F). In its first month Salugen's share price increased over 70 percent despite uncertain economic times affecting the overall equity markets and is currently near its listing price.

The Company is raising capital to invest in growing its commercial infrastructure in Europe and the USA, as well as exploring further growth through additional acquisitions. The banking institutions involved in the transaction include investment bank Sherbrooke Equity AG.

Salugen began in early 2005 as a pioneer in nutritional genetics. In a few short years, the Company emerged from its "pilot stage" positioned to capture significant market share. Besides winning numerous awards for its research by the Natural Products Association, the largest natural products association in North America, some of the accomplishments of the first three years include:

- Conducting a dozen commercial pilots in Europe and the USA to evaluate the viability of nutrigenomics for joint health, obesity, alcoholism, illegal drug abuse, narcotic abuse, skin health, stress and other conditions;
- Gaining rights to multiple issued and pending intellectual property protections in Europe and the USA, as well as registering important trademarks;
- Completing multiple clinical studies and having over 15 publications in peer-reviewed scientific and medical journals;
- Going from start-up to about \$1M in sales in its first year of commercial piloting demonstrating explosive growth potential; and,
- Accomplishing these features on less than 1/10th of the funding of other companies in nutritional genetics.

To prepare Salugen for this milestone, the Company has participated in various programs to support its growth including being a member of the Morrison & Foerster Venture Network ([www.mofo.com](http://www.mofo.com)), a graduate of the San Diego CONNECT Springboard Program ([www.connect.org](http://www.connect.org)), and a presenter at the Nutritional Capital Network ([www.nutritioncapital.com](http://www.nutritioncapital.com)).

This release follows a German news release on April 13, 2009 [http://www.irw-press.com/news\\_6944.html](http://www.irw-press.com/news_6944.html).

### About Salugen AG

Salugen™ is a life sciences company offering nutritional ingredients and gene testing to help reduce excessive cravings involved in smoking, weight problems, and alcohol and drug abuse. Salugen has a patent-protected, clinically proven nutritional formulation to reduce stress and cravings, as well as patent-protected gene tests to help identify these persons and customize their treatment. Simply, Salugen's goal is to reduce or eliminate the illness, costs, and deaths associated with these preventable disorders. For additional information about the



company, please visit <http://www.salugen.com>.

Investor Relations Information Contact:

Petjo Noack, MA and Louis Philippe Antunes

Sherbrooke Equity Inc.

Seefeldstrasse 45

8032 Zürich

Tel.: 41 (0) 43 443 70 70

Fax.: 41 (0) 43 443 70 77

Web: [www.sherbrookequity.com](http://www.sherbrookequity.com)

Company Information Contact: Salugen AG, 877-258-4360

Forward Looking Statements

Certain statements in this press release are forward-looking. These forward-looking statements include references to the use of our laboratory tests and nutritional products. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that physicians may not use the testing or products correctly; risks and uncertainties relating to the performance of our products; the growth in revenues; the size, timing and success or failure of any clinical trials; whether larger confirmatory clinical studies will confirm the results of initial studies; our ability to establish reliable, high-volume operations at commercially reasonable costs; expected reliance on physicians selling our products for a majority of our revenues; the annual renewal of certain customer agreements; actual market acceptance of our products and adoption of our technological approach and products; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services; whether actions by the FDA, FTC or any other state regulatory body will restrict our ability to commercialize our products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; and whether we will be able to raise sufficient capital in the future, if required. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

###

**Contact Information****Brian Meshkin**

Salugen AG

<http://www.salugen.com>

951-719-4242

**Online Web 2.0 Version**You can read the online version of this press release [here](#).



## **FGR006SRB : 13.56MHz [MIFARE] Fingerprint-Stored Smart Card Reader**

*The FGR006SRB is perfect for those who crave for high security level, privacy protection, and unlimited fingerprint user expansion.*

Seoul, Korea (PRWEB) July 13, 2009 -- IDTECK's (<http://www.idteck.com>) FGR006SRB is a fingerprint-recognition smart card reader for access control and time & attendance. Even with the easy-to-install feature, it is designed to provide the highest security available.

One of the notable features is that the FGR006SRB allows you to store your personal bio data on the smart card using the PRG2000B programmer, which eliminates the need for managing database or templates separately.

The fingerprint-stored smart card technology has several remarkable benefits. Since the biometric data of the card holder is saved onto the card rather than inside the reader, the concern about the privacy of the card holder, i.e. biometric features, is effectively eliminated.

This technology also allows the system to accommodate an unlimited number of fingerprint users as the decentralized template storage doesn't require large built-in storage memory for fingerprint templates.

IDTECK's wide-ranging product line-up also offers control panels that work in perfect sync with the FGR006SRB and other smart card readers, including the single-door access control panel iCON100SR and the 2 to 4-door access control panel iTDC-SR.

- High Security Level
- Business Protection
- Privacy Protection
- Unlimited Fingerprint User Expansion

### Key Features

&#9642; 13.56MHz [MIFARE] Fingerprint-Stored Smart Card Reader

&#9642; Read Range: Up to 4 inches (10cm)

&#9642; Output Formats: 26bit Wiegand (Default) / RS232 and ABA Track II (Optional)

&#9642; Reads encrypted-IDs of smart cards which can be written by the IDTECK (<http://www.idteck.com>) programmer PRG2000B

&#9642; ID-only verification for users whose fingerprints cannot be registered

###



### **Contact Information**

**Young Kang**

IDTECK

<http://www.idteck.com>

82-2-2659-0055

### **Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **Brooks Instrument Introduces New Liquid Vaporizer Solutions Breakthrough Vaporization Solutions for All Liquid-to-vapor Applications**

*Brooks Instrument, a world-leading provider of advanced flow measurement, control, and level solutions, is pleased to introduce a family of extremely high-performing direct liquid injection (DLI) vaporizer solutions. Designed for customers who require reliable liquid vaporization, the unique Brooks DLI vaporizers deliver chemically pure vapor in every application.*

Hatfield, PA (PRWEB) July 12, 2009 -- [Brooks Instrument](#), a world-leading provider of advanced flow measurement, control, and level solutions, is pleased to introduce a family of extremely high-performing [direct liquid injection \(DLI\) vaporizer solutions](#). Designed for customers who require reliable liquid vaporization, the unique Brooks [DLI vaporizers](#) deliver chemically pure vapor in every application.

"Working with key customers in the semiconductor, solar, fuel cell, glass coating, R&D, and other markets, we've applied our application knowledge to develop the DLI vaporizer," stated Ed Fisher, Solutions Manager at Brooks Instrument. "Each DLI vaporizer is easily customizable for every customer's unique application requirements and also overcomes the many operational limitations of conventional vaporizing technologies such as bubblers, or vapor draw systems, and flash vaporizers. Additionally, none of the conventional vaporizer technologies can eliminate the potential for liquid carry-over and its attendant problems like a DLI vaporizer."

A Brooks DLI vaporizer employs heated gas, rather than a hot metal surface, to accomplish liquid vaporization. As liquid enters the heated gas chamber, it is atomized by a carrier gas stream. Once the atomized liquid contacts the hot gas, it immediately changes to vapor. The result is chemically pure vapor, free of decomposition byproducts or liquid carry-over. Moreover, a Brooks DLI vaporizer can accept multiple liquid inlets and will generate perfectly mixed vapors. Brooks offers vaporizer designs to accommodate an extraordinarily wide range of liquid properties: extremely low vapor pressures (sub 1 torr), very low flow rates (sub 5 grams per hour), and very high flow rates (more than 15 kg/hr). Unlike bubblers and hot-surface vaporizers, Brooks DLI vaporizers are extremely efficient at producing vapor from liquid.

Every Brooks DLI vaporizer system is perfectly tailored to each customer's specific requirements and can be delivered as a fully integrated system or as individual components. For more information about a DLI vaporizer system or to contact your local Brooks expert, visit [www.BrooksInstrument.com](http://www.BrooksInstrument.com).

### About Brooks Instrument

Brooks Instrument, LLC, based in Pennsylvania, is a company of highly trained specialists whose goal is to provide flow solutions that exceed customer expectations. The Company has a proven history of innovation including the first miniaturized Coriolis mass flow controller (Quantim), the first watertight and explosion proof thermal mass flow controller (Mf Series), the first thermal mass flow controller with Foundation Fieldbus (SLA Series), and the first variable area meter with Foundation Fieldbus (MT3809 & MT3750). Today, Brooks Instrument's portfolio includes glass and metal tube variable area meters (rotameters), thermal mass flow controllers and meters, Coriolis mass flow controllers, meters and transmitters, pressure control products, magnetic level instruments, and a variety of flow accessories. The Company also owns Key Instruments which offers precision machined acrylic flow meters, molded plastic flow meters, glass tube flow meters, electronic flow



meters, and flow control valves. Brooks Instrument has manufacturing locations, sales, and service offices in the Americas, Europe, and Asia. For more information on flow solutions, products, or sales contacts please visit [www.BrooksInstrument.com](http://www.BrooksInstrument.com).

###

**Contact Information**

**Jim Hollis**

Brooks Instrument

<http://www.BrooksInstrument.com>

215.362.3527

**Online Web 2.0 Version**

You can read the online version of this press release [here](#).

**News Image**





## **DIA Workshop Features Industry and FDA for Discussion of Best Practices for Electronic Establishment Registration and Product Listing**

*August 11-12 in Philadelphia, PA*

Horsham, PA (Vocus) -- The [Drug Information Association](#) (DIA), in collaboration with the Generic Pharmaceutical Association (GPhA), PhRMA, and the Consumer Healthcare Products Association (CHPA), will host [eDrug Listing and Establishment Registration--FDA and Industry: Overview and Lessons Learned on SPL](#) (August 11-12; Philadelphia, PA)

The FDA Amendments Act (FDAAA) mandated the requirements for electronic drug establishment registration and drug product listing. FDA has adopted the use of extensible markup language (XML) files in a standard structured product labeling format as the standard format for the exchange of drug establishment registration and drug product listing information. Featured topics will include:

- \* Lessons learned from the electronic registration/drug product listing pilot
- \* Validation rules applied by FDA
- \* Nuances of SPL lifecycle management, including findings from the electronic listing pilot and early production submissions.
- \* SPL Release 4 terminology
- \* Product listing and establishment registration for various complex scenarios (e.g., export only products, product kits, etc.)

The SPL Vendor Showcase will provides an opportunity for attendees to evaluate a number of currently available services and tools as they are used to produce an equivalent final product. During this session, participating vendors will demonstrate their services and/or tools and present their results.

The SPL Live Q&A will allow attendees to ask key FDA representatives about electronic establishment registration and product listing regulatory content, SPL technical content, or the ESG submission process

"This one-of-kind event is the only opportunity to hear industry and FDA representatives discuss best practices for electronic establishment registration and product listing," says Program Co-chair Therese Brunone, MS, Assistant Director, Global Regulatory Operations, GlaxoSmithKline.

About the Drug Information Association (DIA)

DIA serves more than 30,000 professionals involved in the biopharmaceutical industry and regulatory affairs worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit [www.diahome.org](http://www.diahome.org) or call 215-442-6100.



Contact: Joe Krasowski  
215-293-5812

###



### Contact Information

**Joe Krasowski**

Drug Information Association

<http://www.diahome.org/DIAHOME/Education/FindEducationalOffering.aspx?productID=20798&eventType=Meeting>

215-293-5812

### Online Web 2.0 Version

You can read the online version of this press release [here](#).

### News Image





## **New Jersey Hospital Protects Patient Safety with Advanced Pharmacy Automation Solution**

*Swisslog's PillPick automated drug management system revolutionized the way hospital pharmacy prepares, dispenses and returns medications.*

Denver, CO (PRWEB) July 9, 2009 -- For more than 80 years, Holy Name Hospital in Teaneck, N.J., has provided healthcare excellence, compassionate medical and nursing care, and introduced technological advances in patient care. Continuing with its tradition of "first-rate patient care," Holy Name Hospital installed Swisslog's PillPick® automated drug management system.

The PillPick automated drug management system reduces medication errors by limiting the number of hands each dose must pass through to get to the patient. PillPick dispenses over 5,000 unit doses daily to Holy Name's 360 beds. The PillPick system's integrated components automate packaging, dispensing and storage while minimizing human intervention. The packaging modules prepare unit doses from bulk stock, and can over-wrap vials, cups, ampoules, syringes and blisters.

PillPick's DrugNest storage module at Holy Name is designed to hold 35,520 unit doses with expansion capabilities of up to 44,400 unit doses. The doses are simultaneously stored and dispensed into first doses and cart fill, streamlining the inventory management process. The patented PickRing assembles unit doses onto a flexible ring for 24-hour patient administration, cassette fill or for dispensing cabinet restocking. At Holy Name, bulk tablets and capsules are loaded into PillPick and packaged into unit dose bar-coded bags. Unit doses are then assembled into PickRings for patient administration. The rings are stored in a carousel, handpicked and delivered to the patient.

Since its installation in September 2007, Holy Name's PillPick drug management system revolutionized the way the pharmacy prepares, dispenses, and returns medications. Pharmacy Director, Rosario Lazzaro, MS, RP said, "Our CEO wants a 'just-in-time' delivery of the most current medications to the patients, with Swisslog's PillPick system, we are getting closer!" Before dispensing to the patient, both the dose and the patient's identification bracelet are scanned to ensure they are receiving the proper medication. Holy Name has seen fewer medication dosage mistakes due to this bar-coding technology.

### **About Holy Name Hospital**

Holy Name Hospital is a fully accredited, not-for-profit, acute care community hospital located in Teaneck, New Jersey. Founded and sponsored by the Sisters of St. Joseph of Peace in 1925, the hospital is now a comprehensive 361-bed medical center offering leading-edge medical practice and technology, administered in an environment rooted in a tradition of compassion and respect for every patient. Affiliation with the New York-Presbyterian Healthcare System brings further advantages to our Bergen County community, including access to clinical trials, highly specialized physicians, and expanded opportunities for professional medical education.

### **About Swisslog**

Swisslog is a global provider of integrated logistics solutions for warehouses, distribution centers and hospitals. Its comprehensive services portfolio ranges from building complex warehouses and distribution centers to



implementing Swisslog's own software to intra-company logistics solutions for hospitals.

Swisslog's solutions optimize customers' production, logistics and distribution processes in order to increase flexibility, responsiveness and quality of service while minimizing logistics costs. With years of experience in the development and implementation of integrated logistics solutions, Swisslog provides the expertise that customers in more than 50 countries around the world rely on.

Headquartered in Buchs/Aarau, Switzerland, Swisslog currently employs over 2,000 staff in about 20 countries worldwide. The group's parent company, Swisslog Holding AG, is listed on the SIX Swiss Exchange (security number: 1232462, Telekurs: SLOG, Reuters: SLOG.S). For more information, visit [www.swisslog.com](http://www.swisslog.com).

Swisslog's Healthcare Solutions division is the world leader providing logistics automation mainly for healthcare markets. Swisslog has installed hospital material transport and pharmacy automation systems in more than 2,000 hospital and pharmacies throughout the world. Swisslog offers total system design, manufacturing, installation and customer support providing a complete hospital supply chain management approach to logistics challenges. Swisslog Healthcare Solutions division headquarters is located in Denver, CO.

###



**Contact Information**

**CHARLES WARREN**

Swisslog

<http://www.swisslog.com/index/hcs-index.htm>

303-373-7923

**Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **International Process Solutions, Inc. Achieves ISO/IEC 17025:2005 Accreditation**

*International Process Solutions, (IPS) based in San Carlos, California, a leader in providing calibration and equipment maintenance service to the biotech and pharmaceutical industries announced today that it has achieved ISO /IEC 17025:2005 accreditation in the field of calibration. International Process Solutions' scope of accreditation includes parameters in electromagnetic, thermodynamic and dimensional measurement.*

San Carlos, CA (PRWEB) July 9, 2009 -- International Process Solutions, (IPS) based in San Carlos, California, a leader in providing calibration and equipment maintenance service to the biotech and pharmaceutical industries announced today that it has achieved ISO /IEC 17025:2005 accreditation in the field of calibration. International Process Solutions' scope of accreditation includes parameters in electromagnetic, thermodynamic and dimensional measurement.

Accreditation to ISO 17025 establishes that measurements within an organization's scope of accreditation are traceable to the International System of Units, (SI), that measurement uncertainty is defined for those measurements and that the organization's quality systems conform to ISO:9001.

"Our accreditation confirms that we are very serious about the field of measurement," said Thomas Main, President of International Process Solutions. "As the only company in the Western United States that can provide ISO 17025 traceable calibration of GE Kaye Validators, IRTDs SIMs and RH instruments, this will bring enormous added value to the region's biotechnology and pharmaceutical industries."

### About IPS:

International Process Solutions was founded in 1997 to provide a superior, focused approach for the support of equipment - providing equipment focused cGMP support for the biotech, pharmaceutical and medical device industries.

The company's services include on-site calibration, maintenance, document generation and validation. IPS understands the requirements from the pre-clinical start-up, to the established, worldwide producer of FDA approved products, including OEMs that require a skilled and capable field service representative. IPS guarantees that all work is carried out by personnel who understand cGMP, procedural and documentation requirements, and last but not least, who understand the criticality of timeliness. The founders of International Process Solutions bring together unique skills enabling field support for a broad range of equipment.

### Contact:

Thomas Main, CEO  
(650) 595-7890, ext 105  
[www.IPS-US.com](http://www.IPS-US.com)

###

**Contact Information****Thomas Main**

International Process Solutions

<http://www.IPS-US.com>

650 - 595-7890

**Online Web 2.0 Version**You can read the online version of this press release [here](#).

## **PharmSource Releases White Paper on Role of U.S. Foreign Corrupt Practices Act (FCPA) in the Bio/Pharma Industry**

*PharmSource Information Services, Inc. announces the publication of a new white paper - "The U.S. Foreign Corrupt Practices Act (FCPA): How to Minimize Your Risk." This incisive resource provides guidelines on how to establish a strong FCPA compliance program that minimizes corruption risk for companies doing business throughout the world. "The U.S. Foreign Corrupt Practices Act (FCPA): How to Minimize Your Risk" is valued at \$495, but will be offered as a free download for a limited time only, from July 8 through July 21, 2009 at [www.pharmsource.com/white-paper](http://www.pharmsource.com/white-paper).*

Fairfax, Va. (PRWEB) July 8, 2009 -- PharmSource Information Services, Inc., a respected provider of business intelligence on contract drug development and manufacture, is pleased to announce the publication of a new white paper - "The U.S. Foreign Corrupt Practices Act (FCPA): How to Minimize Your Risk." This incisive resource provides guidelines on how to establish a strong FCPA compliance program that minimizes corruption risk for companies doing business throughout the world.

"The U.S. Foreign Corrupt Practices Act (FCPA): How to Minimize Your Risk" is valued at \$495, but will be offered as a free download for a limited time only, from July 8 through July 21, 2009 at [www.pharmsource.com/white-paper](http://www.pharmsource.com/white-paper). This proprietary white paper includes detailed information on:

- \* Industry-specific implications of current FCPA regulations.
- \* Essential elements of a strong FCPA compliance program for those in the bio/pharma industry.
- \* Comprehensive steps to implement a solid FCPA compliance program.
- \* Enforcement of anti-corruption business practices in emerging markets.
- \* Mechanisms to avoid compliance pitfalls despite global and economic challenges.

"This report provides priceless strategic insights on FCPA compliance programs, which could save bio/pharma companies millions of dollars in fines and losses due to an unintended corruption scandal," advises PharmSource founder and president, Jim Miller.

The U.S. is increasing the number of investigations of FCPA and financial fraud violations, particularly within the pharmaceutical sector. This has been reflected by an increase in enforcement budgets and the employment of additional personnel to improve the frequency with which investigations are conducted. Readers will find this timely publication to be a critical first step in understanding FCPA practices and ensuring the protection afforded by a robust compliance program, especially while conducting business in emerging markets.

"[After all, it is far easier to start a compliance program before commencing work overseas than it is to implement one retroactively, but it is also far more cost-effective to implement and run a compliance program than it is to be involved in any kind of FCPA investigation, which not only is costly but can have devastating effects on a company's reputation and business," comments Leslie McCarthy, director of corporate development at The STEELE Foundation, in the white paper.



If you would like to obtain a copy of "The U.S. Foreign Corrupt Practices Act (FCPA): How to Minimize Your Risk," please contact PharmSource via e-mail at [info@pharmsource.com](mailto:info@pharmsource.com) or call 1-703-383-4903 (USA ET).

#### About PharmSource

PharmSource is a respected provider of business intelligence on contract drug development and manufacture. A premier information resource for both biotechnology/pharmaceutical sourcing executives and contract service providers since 1996, PharmSource has provided organizations involved in contract pharma services with publications, databases, surveys and consulting services. Companies from around the world continually rely on PharmSource's deep industry expertise and analyses to help them make smarter strategic business decisions.

#### About PharmSource ADVANTAGE

PharmSource ADVANTAGE online service is one of the industry's most respected outsourcing information web portals for serious consumers of information on contract drug development and manufacturing. This strategic resource allows subscribers to receive industry insight and analysis through two regular publications - Bio/Pharmaceutical Outsourcing Report and Emerging Markets Outsourcing Report. It also includes full access to PharmSource's highly regarded database of contract service providers, where subscribers can search for and compare hundreds of companies from around the world that serve the pharma industry.

###



**Contact Information**

**Eurona Earl Tilley**

PharmSource Information Services, Inc.

<http://www.pharmsource.com>

1-703-383-4903

**Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **McCulley/Cuppan Sets Jul-Sept Dates for Suite of Web-Based Technical Writing Courses**

*McCulley/Cuppan announced today the summer dates for their web-based training programs for professionals in the biopharmaceutical and life science industries. The web delivered "short" courses are one hour in duration and designed specifically for the busy professional looking to refine their technical writing skills.*

Salt Lake City, Utah (PRWEB) July 8, 2009 -- McCulley/Cuppan announced today dates for their series of web-based training programs for professionals in the biopharmaceutical and life science industries. The web delivered "short" courses are one hour in duration and designed specifically for the busy professional looking to refine their technical writing skills.

The webinars will be delivered by McCulley/Cuppan facilitators as "virtual" training sessions on the following dates:

Managing the Message in Your Technical Report offered July 22, August 26, and Sept 16, 2009

Whether you do academic, professional, or regulatory writing--command and sustain your readers' attention by writing powerful paragraphs and carefully managed messages.

Writing for the Regulatory Reader offered September 30, 2009

Learn more on how you can save time and effort with tested strategies for planning and tailoring your writing to the regulatory reading audience and effectively managing purpose and presenting your arguments in a logical manner for the regulatory reader.

Writing High Quality Method Validation Reports offered July 29 and September 23, 2009

A narrowly focused workshop that explores the key features of truly high-quality method validation reports. Topics will range from role and purpose of each section in a validation report, to writing effective summaries and development histories, to design of highly effective, easily read tables.

More details for each webinar short course can be found on the McCulley/Cuppan web site (<http://www.mcculley-cuppan.com>)

"We understand that many professionals do not have the time to attend skill seminars that take them away from the workplace for a half or a full day. Additionally, most people do not find sitting in a webinar for three plus hours to be an appealing way to learn new concepts. Hence the creation of the suite of one hour webinars that focus on narrowly defined elements of scientific and regulatory writing." said Burke Johnstun, E-learning Program Manager at McCulley/Cuppan.

The design of each Short Course Webinar is based on the collective experience of McCulley/Cuppan consultants working the past 16 years in developing and delivering training to biopharmaceutical and medical device companies and a deep understanding of how to design web-based training for the workplace setting. "We receive a considerable number of comments from participants that they find these short courses to be time well spent." commented Gregory Cuppan, Managing Partner of McCulley/Cuppan LLC. "We have packed each course with



an incredible amount of information and tools that participants will use time and time again in the workplace."

#### About McCulley/Cuppan

Since 1994 McCulley/Cuppan, a Salt Lake City-based training and consulting group, has been a partner, pathfinder, and facilitator in helping clients succeed with their regulatory documentation and improve organizational work practices. The focus of the E-learning Division is to provide high quality web-based training courses that will help refine workplace skills and improve document quality. McCulley/Cuppan provides consulting, training, and writing support only to the pharmaceutical and medical device industries.

###



**Contact Information**

**GREGORY CUPPAN**

McCulley/Cuppan LLC

<http://www.mcculley-cuppan.com>

801-685-7717

**Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **The DNA Shoah Project Collaborates with Hewlett-Packard 'Innovations in Education' Grantee**

*The University of Arizona's DNA Shoah Project will provide laboratory facilities and expertise to students participating in Palo Verde High School's Annealing Project, an interdisciplinary approach to teaching diversity and human identity. Tucson Unified School District's Palo Verde High Magnet School was one of only 25 schools in the United States to receive a grant from HP's 'Innovations in Education' program, designed to raise student achievement in math and science and increase awareness in high-tech college and career opportunities. The award brings \$265,000 of technology, cash and professional services to the school and gives students the opportunity to experience state-of-the-art laboratory practices in the workplace.*

Tucson, AZ (PRWEB) July 8, 2009 -- The DNA Shoah Project's mission to reunite families torn apart by the Holocaust will be brought to life this fall in Palo Verde High Magnet School classrooms through a special project designed to combine cutting-edge genetics, computer technology and the humanities. Aptly entitled The Annealing Project, this educational collaboration is funded by a \$265,000 HP Innovations in Education grant.

The DNA Shoah Project, a division of the University of Arizona's Arizona Research Laboratories, is a non-profit, humanitarian effort to build a database of genetic material from Holocaust survivors and their immediate descendants in an attempt to reunite families. The DNA Shoah Project's laboratory resources will make "citizen scientists" of the Palo Verde High Magnet students and enable them to participate in the hands-on analysis of DNA samples from Holocaust survivors. The DNA Shoah Project's multimedia curriculum, comprised of science-based learning activities mixed with Holocaust survivor testimonies, will bring lessons of the Holocaust into the high school's biology, mathematics and humanities classrooms. Annealing Project students will also assist with hands-on analyses of DNA samples from Holocaust survivors and learn to record valuable survivor interviews.

The Annealing Project uses an interdisciplinary approach to address issues of human identity, diversity and belonging. Biology, biotechnology and mathematics students will receive a real-world introduction to molecular genetics, forensics science and professional laboratory practices while they assist with DNA Shoah Project data analysis. English and social studies students will learn to take videotaped and recorded testimonies from Holocaust survivors, collecting material for an interactive, online archive and social network that will allow survivors to connect with one another from all over the world. Not only will Annealing Project students gain a technological literacy and marketable skills through these experiences, they will learn that the disparate members of their diverse student body are more alike than different.

Palo Verde Biology/Biotechnology teacher, Kevin Kehl, team leader for the Annealing Project, works with many students who are often the first high school graduates in their families and may be the first college attendees as well. Kehl sees the PVHS/DNA Shoah Project collaboration as an opportunity to "bridge the gap" that might otherwise exist between these students and a post-secondary learning environment and the grant from HP as one that will fundamentally redesign the student learning experience.

Worldwide, HP is investing more than \$17 million in mobile technology, cash and professional development as



part of the global 2009 HP Innovations in Education grant initiative. This initiative follows HP's five-year, \$60 million investment in HP Technology for Teaching grants to more than 1,000 schools and universities in 41 countries. During the past 20 years, HP has contributed more than \$1 billion in cash and equipment to schools, universities, community organizations and other nonprofit organizations around the world.

"Innovation is key to expanding education opportunity - and HP is privileged to collaborate with educators around the world who are committed to exploring the exciting possibilities that exist at the intersection of teaching, learning, and technology," said Jim Vanides, Worldwide Program Manager for HP Global Social Investments. "Emerging evidence from the last five years is very positive - excellent instruction combined with the right technologies is measurably improving student academic success."

More information about the 2009 HP Innovations in Education initiative and other global social investments is available at [www.hp.com/go/grants](http://www.hp.com/go/grants)

Kevin Kehl, Annealing Project team leader, can be emailed at [kevin.kehl\(at\)tusd1\(dot\)org](mailto:kevin.kehl@tusd1.org) . More information on Palo Verde Magnet High School and its Science Department is available at <http://edweb.tusd.k12.az.us/pvscience>

#### About the DNA Shoah Project:

The DNA Shoah Project is a non-profit, humanitarian effort housed at the University of Arizona aiming to reunite families torn apart by the Holocaust. The Project is building a database of genetic material from survivors and their immediate descendants in an attempt to match displaced relatives and provide Shoah orphans and lost children with information about their biological families. There is no cost to participate. Donations are tax-deductible. Please visit <http://www.dnashoah.org> for additional information.

#### DNA Shoah Project Media Contact:

Lynn Davis  
520-626-6203  
[lynn\(at\)dnashoah\(dot\)org](mailto:lynn@dnashoah.org)  
<http://www.dnashoah.org/>

#### DNA Shoah Education Coordinator:

Barbara Fransway  
520-626-1672  
[bbf\(at\)email.arizona\(dot\)edu](mailto:bbf@email.arizona.edu)  
<http://www.dnashoah.org/>

#### About Arizona Research Laboratories

The University of Arizona's Arizona Research Laboratories (ARL), comprises a group of researchers solving critical scientific problems and generating knowledge for the future. The organization's structure and values promote innovation through dynamic interdisciplinary collaborations. ARL has been a leader in interdisciplinary science and research for almost 30 years.



ARL Contact:

Michael Cusanovich, Ph.D.

Cusanovi(at)u.arizona(dot)edu

520-621-7533

www.arl.arizona.edu

PO Box 210077

Tucson, AZ 85721-0077

###



### **Contact Information**

**Lynn Davis**

The DNA Shoah Project

<http://www.dnashoah.org>

520-626-6203

### **Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **MediSend International Hosts Graduation for Ten Biomedical Trainees from Africa**

*The trainees have now returned to hospitals in their countries as certified biomedical technicians with the skills to install, repair and maintain life-saving biomedical equipment.*

Dallas, TX (PRWEB) July 8, 2009 -- Guests including board members, donors, partners and friends gathered at MediSend International's Global Education Center to attend a graduation ceremony honoring ten biomedical repair trainees from African hospitals on Saturday, June 20th. Trainees from Liberia, Chad, Equatorial Guinea and Nigeria have now returned home after completing the 2009 Spring-Summer Biomedical Repair Training Program. MediSend's intensive, outcomes-oriented, six-month Biomedical Repair Training Program is the first such program to train BMET technicians for developing country hospitals.

"We are going home with the ability to improve conditions in our countries," said Gabriel Akuboh from Nigeria who spoke on behalf of the trainees, "We will carry on MediSend's mission of sending hope and saving lives."

ExxonMobil funded the program for the trainees from Chad, Equatorial Guinea and Nigeria. The long-standing ExxonMobil and MediSend alliance has trained over 30 BMET certified biomedical repair technicians for under-resourced hospitals in five countries in Africa. The students from Liberia were sponsored by the Zoe-Geh Foundation.

Each graduate technician's hospital will receive MediSend's Mobile Biomedical Equipment Test and Repair Kit™ designed to withstand the harsh conditions such as temperature, humidity and unstable energy often experienced in the developing world. Containing over 4000 laboratory repair tools, supply items and state-of-the-art test and calibration equipment essential to the repair and maintenance of biomedical equipment, the kit is the foundation for a modern biomedical repair laboratory, and has the capacity to repair and maintain approximately eighty percent of all basic biomedical equipment used in a developing hospital system.

"This is the third year that we have trained qualified biomedical repair technicians at MediSend International. All technicians return home highly trained and skilled to elevate the level of healthcare in their communities and empowered to improve the lives of thousands of individuals." said Nick Hallack, President and CEO of MediSend International.

For more information on MediSend, go to [www.medisend.org](http://www.medisend.org)

About MediSend:

MediSend is a 501(c)(3) nonprofit, humanitarian organization that supports under-resourced hospitals in developing countries with a multi-dimensional approach to improving community health. MediSend's mission includes education, training, technical support and management technologies in Biomedical Equipment Repair, as well as the distribution of life-saving medical supplies and biomedical equipment in long-term partnership programs and emergency relief programs.



###



**Contact Information**

**LOU ANN YORK**

MediSend International

<http://www.medisend.org>

214-343-1599

**Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **VerteLoc™ Tops 500 Surgical Procedures, VGI Announces VerteLX™ and Seeks Potential Investors for Growth**

*The VerteLoc™ Minimally Invasive Spine Stabilization system has now been implanted in more than 500 patients across the United States. Surgeon acceptance of the surgical procedure continues to drive record growth. VGI will pursue its first FDA 510K on another device, VerteLX™, for the treatment of lumbar spinal diseases that require fusion.*

Winston-Salem, NC (PRWEB) July 7, 2009: VG Innovations, Inc (VGI), announced today that its revolutionary VerteLoc™ Minimally Invasive Spine Stabilization system has now been implanted in more than 500 patients across the United States during its first year on the market.

VerteLoc™ is designed to address back pain, created by minor spinal instabilities, by effectively stabilizing the spinal facets, which are multi-directional joints of the spinal column.

"The VerteLoc™ system has now been utilized in more than 500 surgical cases," stated VGI's President and CEO, Dan Grayson. "It is making a significant difference in the way back pain is being addressed, allowing for earlier intervention to avoid more invasive surgical procedures. Surgeon acceptance of the VerteLoc™ system continues to experience a phenomenal rate of growth, especially through the conversion of competitive business. Through the end of Q2 2009, we have exceeded revenue projections by 156%."

VGI will enter into a new arena later in 2009, pursuing its first FDA 510K on another device, VerteLX™, for the treatment of various spinal diseases that require fusion of the lumbar spine.

"There are numerous systems / devices on the market that are inserted from an anterior, posterior or lateral surgical approach," Grayson elaborated. "Many current systems, that are classified as 'minimally invasive' still offer instrumentation that is bulky and sometimes difficult to use inter-operatively. VGI will introduce a system that utilizes just a few small instruments for the lateral surgical approach and insertion of a unique biomechanically superior implant."

The VerteLX™ implant is like nothing ever seen previously in the spine market. VGI will demonstrate the VerteLX™ system at the North American Spine Society meeting in November with a limited product launch planned for Q2 2010. "VGI is entertaining the idea of a potential investor or partner to expand distribution to a broader market," Grayson continued. "We believe surgeon demand for the VerteLX™ product will be so great that we may require additional resources to allow for rapid expansion."

### **Company Profile**

VG Innovations, Inc, (VGI) is a privately held company and was formed in late 2007. The company is in the business of developing and commercializing proprietary, implantable devices with a specific focus on minimally invasive surgical products that could provide better surgical solutions over present technology. The products are designed to treat specific spinal disease indications that affect millions of people. More information on the company and its products can be found at: [www.verteloc.com](http://www.verteloc.com)



###



### **Contact Information**

**Libby Motto**

VG Innovations, Inc

<http://www.verteloc.com>

336-760-2012

### **Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **Burnham Institute for Medical Research and Magellan BioScience Group, Inc. Announce Drug Discovery Collaboration**

*Magellan BioScience Group, Inc. (Magellan), a pioneer in innovative drug development from marine sources, and investigators at the Burnham Institute for Medical Research at Lake Nona (Burnham) announced today that they will begin a multidisciplinary drug discovery collaboration to identify novel marine microbial compounds that have potential as tools for biological research and ultimately the discovery of new medicines.*

Tampa and Orlando, FL (Vocus) July 7, 2009 -- Magellan BioScience Group, Inc. (Magellan), a pioneer in innovative drug development from marine sources, and investigators at the Burnham Institute for Medical Research at Lake Nona (Burnham) announced today that they will begin a multidisciplinary drug discovery collaboration to identify novel marine microbial compounds that have potential as tools for biological research and ultimately the discovery of new medicines.

This collaboration will bring together Magellan's unique collection of marine-derived microorganisms and their natural product chemistry expertise with Burnham's ultra-high throughput small molecule screening technologies that were recently established at the Lake Nona, Florida campus. The Burnham-Magellan team will utilize Burnham's state-of-the-art robotic screening system to run bioassays and characterize lead candidates from the collection. The Burnham team of Medicinal Chemists will then optimize novel compounds to afford potential biological probes and preclinical drug candidates. The groups' combined expertise in sophisticated chemistry approaches and access to advanced screening technologies, will accelerate early discovery and drug development efforts.

"We are excited to initiate this discovery collaboration with Burnham," said Dr. Todd R. Daviau, CEO of Magellan. "Burnham's scientific and technological approach coupled with their highly-qualified and industry-experienced research teams constitutes a significant opportunity for the discovery and development of new pharmaceutical candidates."

Burnham's ultra-high throughput screening resource resides within the Conrad Prebys Center for Chemical Genomics and is one of four NIH sponsored comprehensive screening and probe development centers in the United States. The fully-integrated automated system combines robotic screening with high-content image analysis, hit-to-probe chemistry, exploratory pharmacology expertise, and informatics, provides a technology platform that is virtually unprecedented in the not-for-profit research world.

"The Burnham-Magellan collaboration will involve some of the first assays to be processed through our new small molecule screening center at Lake Nona. This is a powerful partnership that will advance both science and regional development and is representative of the collaborations that were envisioned by Burnham as we established an east coast campus in Florida," said Dr. Gregory Roth, associate professor and director of medicinal chemistry and pharmacology at Burnham.

About Magellan:



Magellan BioScience Group, Inc., based in Tampa, Fla., is a privately held innovative biotechnology company focused on the discovery of novel classes of therapeutic candidates. Magellan is using its integrated platform technologies to isolate and identify new biologically active compounds. The company believes that its library of marine microbes will be the next source of drug discovery for the pharmaceutical industry. Magellan aims to develop and optimize drug candidates to treat cancer, infectious diseases, and inflammation. For additional information, please refer to the company's web site at [Magellan BioScience Group, Inc.](#).

**About Burnham Institute for Medical Research:**

Burnham Institute for Medical Research is dedicated to revealing the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Burnham, with operations in California and Florida, is one of the fastest-growing research institutes in the country. The Institute ranks among the top-four institutions nationally for NIH grant funding and among the top-25 organizations worldwide for its research impact. Burnham utilizes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration, diabetes, infectious and inflammatory and childhood diseases. The Institute is known for its world-class capabilities in stem cell research and drug discovery technologies. Burnham is a nonprofit, public benefit corporation. For more information, please visit [Burnham Institute for Medical Research at Lake Nona](#).

###



### Contact Information

**Todd R. Daviau, PhD**

Magellan BioScience Group, Inc.

<http://www.magellanbioscience.com>

(727)-865-1300

### Online Web 2.0 Version

You can read the online version of this press release [here](#).

### News Image





## **TRaC Launches ZigBee RF4CE Test Service**

*TRaC has formally launched its ZigBee RF4CE test service allowing certification against this standard.*

Hull, UK (PRWeb UK) July 6, 2009 -- As one of only three ZigBee Alliance recognised test houses, and the only UK based ZigBee recognised test house, TRaC has been providing manufacturers with ZigBee Certification testing for some time. Supporting the new ZigBee RF4CE platform specification issued by the ZigBee Alliance, TRaC has formally launched its ZigBee RF4CE test service allowing certification against this standard.

ZigBee RF4CE is a new generation remote control technology ideally suited for the consumer electronics and home entertainment markets. It offers significant advantages over traditional infrared; it allows communication without the need for direct line-of-sight, and allows for a truly universal remote control. The ZigBee RF4CE certification program ensures full interoperability between different manufacturers. The availability of a global standard for this market is expected to produce a transformation within the home, as devices such as TVs, music systems and satellite boxes, from different manufacturers, can be hidden away and controlled using a single remote. This combination of functionality and interoperability makes the "single remote" concept a reality.

TRaC is actively involved with this exciting new technology and the expertise of TRaC engineers has assisted in making the launch of the ZigBee RF4CE certification program a success. TRaC was actively involved with the certification of the first ZigBee RF4CE "golden" platforms.

According to, Kobus Marneweck, Manager - Low Power Wireless Software, Texas Instruments, "As one of the first manufacturers to obtain ZigBee RF4CE certification, we were very pleased with the professionalism and technical understanding shown by TRaC."

In addition, commenting on TRaC's testing contributions, Victor J Berrios, Global Platform Development Manager, Freescale Semiconductor, Inc said, "We were very happy with TRaC's commitment and investment in ZigBee RF4CE Technology. We look forward to TRaC's continued support of this technology going forward."

"ZigBee Alliance members benefit from the broad testing expertise provided by TRaC," said Benno Ritter, vice president of marketing at the ZigBee Alliance. "Adding TRaC to our list of approved global test houses not only helps our members certify their products faster, but helps us create stronger testing regimens that ultimately allow consumers to buy ZigBee products with confidence."

TRaC are now offering this comprehensive RF4CE platform test service to other designers and will soon follow this with an RF4CE product test service once the ZigBee RF4CE product specification is formally issued.

**ZigBee RF4CE: More flexibility and control**

The ZigBee RF4CE specification is based on IEEE 802.15.4. MAC/PHY radio technology in the 2.4GHz unlicensed frequency band and enables worldwide operation, low power consumption and instantaneous response time. It allows omni-directional and reliable two-way wireless communication, channel agility for enhanced co-existence with other 2.4GHz wireless technologies, simple secure set-up and configuration.



### ZigBee: Control your world

ZigBee is the global wireless language connecting dramatically different devices to work together and enhance everyday life. The ZigBee Alliance is a non-profit association of more than 300 member companies driving development of ZigBee wireless technology. The Alliance promotes worldwide adoption of ZigBee as the leading wirelessly networked, sensing and control standard for use in consumer electronic, energy, home, commercial and industrial areas. For more information, visit: [www.ZigBee.org](http://www.ZigBee.org)

### About TRaC

TRaC is a leading test group with accreditations for all major markets worldwide. It has established itself with a reputation for unrivalled excellence in global approvals, testing and certification. visit: [www.tracglobal.com](http://www.tracglobal.com)

TRaC provide the assessment route to product manufacturers and designers to ensure they fulfill their legal obligations and demonstrate full compliance with the requirements of countries around the world. For more information, visit [www.tracglobal.com/zigbee](http://www.tracglobal.com/zigbee)

###



### **Contact Information**

**Bally Wadalia**

TRaC

<http://www.tracglobal.com>

01684 571700

### **Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **Healthcare Waste Solutions Inc. and Vestara Announce Strategic Partnership Making Available the Most Effective Pharmaceutical Waste Solution**

*Healthcare Waste Solutions Inc. and Vestara announced today the creation of a strategic partnership to work together incorporating the Vestara EcoRex®NS Automated Pharmaceutical Waste Management System into the Healthcare Waste Solutions Inc. Complete Waste Solution™ program. Both Healthcare Waste Solutions and Vestara believe that this strategic partnership enables both entities to further expand operations and assist health systems to manage pharmaceutical waste in the most compliant, safe, and user friendly means possible.*

Cincinnati, OH (PRWEB) July 7, 2009 -- Healthcare Waste Solutions Inc. and Vestara announced today the creation of a strategic partnership to work together incorporating the Vestara EcoRex®NS Automated Pharmaceutical Waste Management System into the Healthcare Waste Solutions Inc. Complete Waste Solution™ program. Both Healthcare Waste Solutions and Vestara believe that this strategic partnership enables both entities to further expand operations and assist health systems to manage pharmaceutical waste in the most compliant, safe, and user friendly means possible.

The incorporation of the Vestara EcoRex®NS System into the Healthcare Waste Solutions Waste Assessment process and Complete Waste Solution™ program will provide the most comprehensive and compliant solution to pharmaceutical waste disposal available. The EcoRex®NS utilizes barcode technology already widely used in hospitals to track drug utilization and prevent medication errors and a proprietary, continuously updated database of more than 160,000 National Drug Code (NDC) products, to instantly categorize pharmaceutical waste at time of presentation. By automating the identification and sorting of different types of residual drugs, empty containers, and each hospital's unique admixtures, EcoRex®NS eliminates the human error and potential cross contamination inherent in manual sorting of pharmaceutical waste to reduce negative impact on the environment. The EcoRex®NS technology together with Healthcare Waste Solutions Inc. disposal solution comprises the best hazardous and non-hazardous pharmaceutical waste solution available to the health care community in the United States.

Healthcare Waste Solutions Inc. was created in response to increased consolidation in the waste industry and a growing lack of alternatives of waste service providers across all waste streams throughout the United States. The Complete Waste Solution™ was created in order to provide an innovative and comprehensive solution for waste management in the healthcare community. It provides a unique solution to a growing problem. The Healthcare Waste Solutions Inc. Assessment Process and Complete Waste Solution™ is a thorough analysis providing specific data on waste stream weights, volumes, price, and true cost as they relate to a health system's Total Waste Spend. In addition, it provides operational assessment, recommendations and training based on patient and employee safety as well as environmental regulatory compliance as they relate to the collection, handling, movement, and storage of waste within health care systems.

Vestara, headquartered in Irvine, CA, ([www.vestara.com](http://www.vestara.com)) provides proprietary technology to automatically identify, sort and segregate the proper disposal of both hazardous and non-hazardous pharmaceutical waste; consequently increasing regulatory compliance and more efficient utilization of hospital staff. Vestara strives to assist healthcare institutions become compliant with existing federal and state RCRA laws via the utilization of its



proprietary technology that identifies pharmaceutical waste and instructs the healthcare provider on the compliant manner in which the waste is to be disposed through the use of Vestara's Automated Pharmaceutical Waste Management System.

###



### **Contact Information**

**James Kim**

Vestara

<http://www.vestara.com>

408-206-7546

### **Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **SciComPro Produces New "Health Today" Talk Radio Program in the Tri-State Region**

*New weekly talk radio show, Health Today, on 55KRC (550 AM) in Cincinnati, Ohio, begins Sunday, July 5, from 6 to 7 pm. Health Today is produced by SciComPro-LLC and sponsored by BIOSTART. Dr. Kurt Weingand is the host and will highlight health news, local health care providers, and a topic of the week with expert guests to answer listeners questions.*

Mason, OH (PRWEB) July 3, 2009 -- BIOSTART will sponsor a new talk radio program entitled "Health Today" that will be produced by SciComPro-LLC and broadcast on Clear Channel Communication's 55KRC (550 AM) in Cincinnati, Ohio beginning July 5, 2009.

"BIOSTART is very excited to be the charter sponsor of Health Today," said Carol Frankenstein, President of BIOSTART. "With this sponsorship, we hope to increase awareness of BIOSTART's services and identify new inventors and investors in health science innovation and start-up businesses," she added.

SciComPro-LLC will produce the new weekly one hour talk radio show with Clear Channel Communications in Cincinnati, OH. "With health care reform around the corner, 55KRC listeners will need new information about health and health care," said Bill Mountel, General Sales Manager, 55KRC. Health Today will air on 55KRC from 6 to 7 PM on Sunday evenings. Each live broadcast will include news on health and health care and a topic of the week with an expert guest to answer questions from listeners. There will also be a segment focusing on the services of local health care providers. Episodes of Health Today will also be available as podcasts on iTunes.

"I am thrilled that BIOSTART has stepped up to support the launch of Health Today in the Tri-State region," said Kurt Weingand, Ph.D, D.V.M., President of SciComPro-LLC in Mason, OH. "People throughout Ohio, Kentucky and Indiana will value highly the Health Today news and information on local health care providers," added Weingand.

Dr. Weingand recently completed a 20 year career at The Procter & Gamble Company working in Research & Development and External Relations in the Global Health & Well-Being business unit. Prior to working at P&G, Weingand was on the faculty at the Wake Forest University School of Medicine and Kansas State University's College of Veterinary Medicine.

### About SciComPro-LLC:

SciComPro is a privately held limited liability corporation in Mason, Ohio, USA that does biomedical research and provides a variety of external relations services for optimizing technical and commercial innovation in new product development and commercial initiatives in the health and pet care categories. For more information on SciComPro-LLC, see [www.scicompro.com](http://www.scicompro.com).

### About BIOSTART:

BIOSTART, Life Science Catalyst and Community, provides life science companies with a proven mix of business and scientific know-how, effective services, cutting edge laboratory facilities and a stimulating, supportive entrepreneurial culture. We help build life science companies that create jobs, build products that



improve health and better the quality of life in the tri-state community. For more information visit [www.biostart.org](http://www.biostart.org)

About 55KRC:

55KRC in Cincinnati, Ohio is owned by Clear Channel and serves the tri-state area with talk and information. 55KRC is the home for Brian Thomas, Glenn Beck, Rush Limbaugh, and Sean Hannity. 55KRC also provides how to advice each weekend from your garden, home or your car from our experts Ron Wilson, Gary Sullivan, Marilyn Harris and Dale Donovan. For more information, see [www.55krc.com](http://www.55krc.com).

###



### **Contact Information**

**Kurt Weingand**

SciComPro-LLC

<http://www.scicompro.com>

513-680-8686

### **Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **METTLER TOLEDO Introduces NewClassic Balances**

*METTLER TOLEDO, a leading global supplier of precision instruments and services is introducing a new balance range, NewClassic, to replace their current Classic portfolio. Suitable for every weighing need, NewClassic MS is a true workhorse setting new standards for durability and ease of operation. A new high-quality robust metal housing offers reliable protection and is resistant to chemicals. The re-designed user-interface allows for intuitive operation, with new SmartKeys to offer direct access to preferred applications. A modern High Contrast Display guarantees error-free reading of results and enhances the user friendliness of the balance.*

Columbus, Ohio (PRWEB) July 1, 2009 -- METTLER TOLEDO, a leading global supplier of precision instruments and services is introducing a new balance range, NewClassic, to replace their current Classic portfolio.

Suitable for every weighing need, NewClassic MS is a true workhorse setting new standards for durability and ease of operation. A new high-quality robust metal housing offers reliable protection and is resistant to chemicals. The re-designed user-interface allows for intuitive operation, with new SmartKeys to offer direct access to preferred applications. A modern High Contrast Display guarantees error-free reading of results and enhances the user friendliness of the balance.

Long-lasting investment in precise results

Only 30 seconds - that's all it takes to dismantle the glass panels and draft shield of the NewClassic MS, making cleaning an easy task. The robust metal housing protects the weighing cell from environmental influences and impacts. Built-in shock and overload protection guarantee a long product life. Still present are the proven MonoBloc weighing cell and FACT, Fully Automatic Calibration Technology, which round out the reasons for world leading weighing results.

The quick way to select the right balance

The virtual showroom ([www.mt.com/newclassic](http://www.mt.com/newclassic)) offers comprehensive information on NewClassic and allows insight into its new functionalities. Short videos demonstrate user operation of the balance, and 3D-animations and an assistant wizard provide quick and valuable guidance on choosing the proper balance.

About METTLER TOLEDO

METTLER TOLEDO is a leading global manufacturer of precision instruments. The Company is the world's largest manufacturer and marketer of weighing instruments for use in laboratory, industrial and food retailing applications. The Company also holds top-three market positions in several related analytical instruments markets and is a leading provider of automated chemistry systems used in drug and chemical compound discovery and development.

Additional information about METTLER TOLEDO can be found at [www.mt.com](http://www.mt.com).

###



**Contact Information**

**Shana Wheeler**

METTLER TOLEDO

<http://www.mt.com/newclassic>

614-438-4936

**Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **iCardiac Selected by Top 10 Pharmaceutical Company**

*Executes Master Services Agreement Covering Highly Automated QT(sm) and Dynamic QTbtb(sm) Solutions*

Rochester, New York (PRWEB) July 2, 2009 -- iCardiac Technologies, Inc., a leader in advanced cardiac safety biomarker development and automated QT analysis, announced that it has executed a master services agreement with a top 10 pharmaceutical company covering both iCardiac's Highly Automated QT as well as Dynamic QTbtb solutions for Phase I and Thorough QT (TQT) studies.

"We are enthusiastic about our continued progress in delivering the next generation of advanced methods for evaluating pharmaceutical cardiac safety," said Sasha Latypova, Executive Vice President. "Our technology and service solution is meeting a critical need for pharmaceutical developers to both increase precision of early clinical cardiac safety studies as well as minimize the current unacceptably high rate of false-positive QTc findings which can lead to unnecessary termination of promising new medicines in development."

### About iCardiac Technologies

iCardiac Technologies, Inc. is a technologically differentiated cardiac core lab providing expert scientific consultation, end-to-end project management, statistical analysis and the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies. iCardiac's analysis service provides drug developers with more precise and cost-effective methods for QT interval measurement, including Highly Automated QT, which has been validated by pharmaceutical companies and accepted by the FDA as equivalent to the manual evaluation of ECGs in Thorough QT studies. In addition, iCardiac provides Beyond QT, a suite of advanced ECG-based cardiac safety markers that have been accepted as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology, and medical device companies. For more information, visit: [www.icardiac.com](http://www.icardiac.com).

###



### **Contact Information**

**Sasha Latypova**

iCardiac Technologies, Inc.

<http://www.icardiac.com>

585-295-7610

### **Online Web 2.0 Version**

You can read the online version of this press release [here](#).

## **Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration**

*Stemedica Cell Technologies, Inc., a leader in the manufacturing and development of clinical grade allogeneic adult stem cell technology, has discovered a significant breakthrough in the use of human stem cells and stem cell factors for the potential treatment of degenerations of the retina and retinal pigmented epithelium.*

San Diego, CA (PRWEB) July 1, 2009 -- Stemedica Cell Technologies, Inc., ("[Stemedica](#)"), a leader in the manufacturing and development of clinical grade allogeneic adult stem cell technology, has discovered a significant breakthrough in the use of human stem cells and stem cell factors for the potential treatment of degenerations of the retina and retinal pigmented epithelium. Retinal degenerations include diseases such as Retinitis Pigmentosa, which are hereditary conditions in which abnormalities of the retinal pigmented epithelium (RPE) within the eye lead to progressive vision loss. According to one of the study's Principle Investigators, Dr. Paul Tornambe, "The results from this pre-clinical experiment are exciting. It allows researchers and clinicians to push the envelope in the quest to use stem cells to modulate diseases like Retinitis Pigmentosa." There is currently no medical treatment that can completely cure Retinitis Pigmentosa - an eye disease that affects approximately 1,500,000 people on a worldwide basis each year.

An international consortium of prominent researchers and clinicians were assembled by Stemedica to fully explore the application of its proprietary lines of stem cells and stem cell factors for treatment of Retinal Degeneration in a pre-clinical environment. Their discoveries provide great promise for treating this disease at a clinical level. "We knew the team assembled had the experience and expertise to fully explore how stem cells and stem cell factors might be applied in the possible treatment of Retinal Degeneration that may apply to Retinitis Pigmentosa in the future", said Nikolai Tankovich, MD, PhD, Stemedica's President and Chief Medical Officer. "While there have been similar results achieved with our stem cells and factors in the experimental treatment of neurological diseases, we did not expect that these efforts would provide the kind of breakthrough results that have been achieved in our ophthalmological study."

The study team was comprised of Edwin Boldrey, MD, a Retina and Vitreous Specialist from Northern California and Charter Member of American Society of Retina Specialists and by Paul Tornambe, MD, of Retinal Consultants in San Diego, California. Dr. Tornambe is a past President of the American Society of Retina Specialists. Other members of the study team included Khristo Takhchidi, MD, PhD; Director General, Natalia Gavrilova, MD, PhD, Professor; and, Olga Komova, MD from the famous Fyodorov Eye Microsurgery Institute in Moscow, Russia. Supporting the principle investigators were Alexander Revischin, PhD, and Irina Saburina, MD, PhD from the Russian Academy of Sciences and by Alexei Lukashev, PhD, of Stemedica's Research Lab in San Diego, California.

Dr. Tornambe identified several observations that resulted from the group's efforts, "There were two very encouraging findings: RPE stem cells injected into the suprachoroidal space prevented the animal's RPE cell's degeneration as well as preventing degeneration of the overlying photoreceptors proven by very objective ERG

testing and histopathology. Secondly, and even more interesting, is that the fellow contra lateral eye also showed a beneficial effect. This crossover effect suggest this treatment stimulated upregulation of other factors, yet unknown, which decreased the rate of degeneration in the fellow eye. Degeneration of RPE cells occur in many other human retinal diseases such as age related macular degeneration. It is very important to temper initial enthusiasm with the test of time, however, this study strongly suggests, at least in this animal model, that certain kinds of stem cells and factors can modify a disease process."

The 18 month pre-clinical study was implemented at the Fyodorov Eye Institute using Stemedica's proprietary multiple cell technology. Three different types of human stem cells (hSC) were used in the study - retinal pigment epithelium (RPE), neural (NSC) and cilliary body (CB) - all obtained from human donor tissue. Various cells were injected into rats with hereditary pigmented degradation of retina. One eye of each participating rat served the treatment eye and the other eye served as the control eye. Healthy non-dystrophic and non-treated (normally dystrophic) animals were also used as independent control groups. Electroretinography (ERG) and immunohistochemical (ICH) analysis was performed on both eyes. "What is very impressive is the immune privileged feature of all three kinds of human stem cells (RPE, CB, NSC) in xenotransplantation. This immune privilege amplifies the significant promise of allogeneic donor stem cells in the treatment of retinal degenerative diseases", stated Dr. Edwin Boldrey.

The research team compared the efficacy of each of the three cell types. A summary of the results yielded the following observations and discoveries:

1. The study showed a statistically significant gain (77%) in the treated eye (with RPE cells) over the control eye of the same animal. However, both the treated eye and the control eye were approximately 10 times more active (response to ERG) compared to non-treated (normally dystrophic) control animal.
2. The RPE and NSC cells were effective in preserving the thickness of the outer nuclei layer of the retina.
3. A contra lateral effect was observed between the test and control eyes. As a result, both eyes exhibited significant improvement. It is believed that the positive outcome in the control eye was achieved through the systemic release of cytokines; growth and other important factors; peptides; and, molecules from stem cells transplanted into the treated eye. This phenomenon is referred to by Stemedica as "The Factor Release Effect" and branded by the company as StemedicaFRE™. These factors, circulating in the blood flow, effect and mobilize endogenous stem cells. Stemedica believes improvement in the contra lateral eye is a 'Factor Release Effect' rather than a Sympathetic Ophthalmic effect which is very rare. Stemedica discovered the presence of these endogenous RPE stem cells in adult retinas several years ago. This original research demonstrated that these RPE stem cells acquired embryonic markers (Nanog and Oct-4) in adult humans.

"Stemedica has filed a number of patent applications to secure the rights for these discoveries - the use of our stem cells and their factors in the treatment of a variety of neurodegenerative diseases and conditions. Based upon the results from the work of this luminary group, we have focused our legal protection and Intellectual Property efforts to include the treatment of Retinitis Pigmentosa and ways to prevent its development and progression", said Timothy Brown, MS, JD, Director of Stemedica's Intellectual Property Department.



The results from the study will be presented at the Retina Congress in New York, September 30, 2009. The Retina Congress is a worldwide gathering of the most established and accomplished retina doctors in the world. The Congress is sponsored by the American Society of Retina Specialists, the Retina Society and the Macular Society and represents over 2,000 retina and eye specialists from 54 countries.

"The discovery of the effect of stem cell factors supports our other clinical evidence substantiating how stem cells and stem cell factors can be isolated and used for the treatment of complex medical conditions. Clinical studies in countries outside of the United States have already demonstrated the efficacy of Stemedica's stem cells and their factors in the experimental study treatment of diabetic retinopathy and other conditions. Based upon this breakthrough discovery and validation of our previous evidence, Stemedica has begun negotiations with a select number of potential strategic partners. Our goal is to rapidly advance our findings into a comprehensive clinical application", said Maynard A. Howe, PhD, CEO and Vice Chairman of Stemedica.

#### Edwin Boldrey, MD

Dr. Edwin Boldrey is currently a Clinical Associate Professor of Ophthalmology at Stanford University and is President of Northern California Retina Vitreous Associates. He is a graduate of Northwestern University Medical School in Chicago and completed a Vitreo-Retinal Fellowship at Barnes Hospital, Washington University, St. Louis. He is the recipient of honors and awards from the American Academy of Ophthalmology, the Heed Ophthalmic Foundation and the Department of Ophthalmology, University of California, San Francisco. He was the Executive Secretary-Treasurer of the Western Retina Study Club, and is a Fellow of the American College of Surgeons. He is a member of Ophthalmological Organizations including: American Academy of Ophthalmology, The American Society of Retina Specialists, The Retina Society and The California Association of Ophthalmology. He is the author of more than 30 peer reviewed publications and has presented 114 papers and courses.

#### Paul Tornambe, MD

Dr. Paul Tornambe is former President of the American Society of Retina Specialists and presently sits on the Board. He has been a member of over a dozen Ophthalmology and Professional Medical Societies including Fellow - American College of Surgeons, American Academy of Ophthalmology, and California Medical Association. He has participated as Chief of Surgery and Chief of Staff at Pomerado Hospital and participated on the Board of Scripps Health Physicians and actively operated at both Scripps La Jolla and Pomerado Hospitals. He completed his Retina Fellowship training at Barnes Hospital, Washington University, St Louis. He is the recipient of numerous awards from the American Academy of Ophthalmology; American Society of Retina Specialists and was named among 'The Best Doctors in America, 2000-2003' along with 'Best Doctors in San Diego, 2002-2005'. He was recognized by the American Academy of Ophthalmology on their Centennial as a physician who made a major contribution in the field of Retina over the last 100 years for his work with gas bubbles to repair retinal detachments. Tornambe is the author of over 40 major peer reviewed scientific publications.

#### Khristo P. Takhchidi, MD, PhD

Khristo P. Takhchidi, is the Director General of the S.N. Fyodorov Federal Institution 'Eye Microsurgery Complex', Professor and the Chairman of Ocular Diseases of the Moscow State Medical University. He received his MD degree in 1976 at Sverdlovsk State Medical University. In 1987 he was appointed the Director of the Ural



Branch of the Intersectional Research and Technology Complex 'Eye Microsurgery'. The IRTC Ural Branch was built and put into operation under his direct leadership. As the Chief of the Clinic, over 260,000 operations were performed and approximately 800,000 patients received diagnostic - consulting service. In 2001 Takhchidi was appointed the Director General of the S.N. Fyodorov Federal Institution 'Eye Microsurgery Complex'. He is an author of over 250 scientific publications, has been the Chair of Ophthalmology Society of Russia since 2005 and was appointed the Chief Expert for ophthalmology of the Russian Federal Inspection for Public Health and Social Development in 2006. Takhchidi is the Fellow of numerous International Ophthalmic societies and a recipient of many prestigious and honorable national and international awards.

#### The Fyodorov Center for Eye Microsurgery

The S.N. Fyodorov Federal State Institution "Eye Microsurgery Center" is the leading clinical and research ophthalmological center in Russia with over 4,000 researchers and medical doctors. The Center, along with its 11 affiliated branches including Clinics in Russia's largest cities, treat 700,000 patients annually, performing 50% of the highly technological ophthalmic surgeries and over 30% of all ophthalmic aid in Russia.

#### About Stemedica Cell Technologies, Inc.

Stemedica Cell Technologies Inc. ([www.stemedica.com](http://www.stemedica.com)) is a specialty biopharmaceutical company that is committed to the development and manufacture of clinical grade allogeneic stem cells for use by approved research institutions and hospitals for pre-clinical and clinical studies. Within the United States, the Company is currently developing regulatory pathways for stroke, traumatic brain injury and wound repair. Outside the United States, Stemedica provides its adult stem cells to hospitals and research centers that are conducting studies under protocols approved by the appropriate regulatory agencies. These studies are focused on the treatment of neurodegenerative disease, sight restoration and wound repair. Stemedica is based in San Diego, California.

Media Contact for Stemedica: Dave McGuigan - [dmcguigan@stemedica.com](mailto:dmcguigan@stemedica.com).

###



### **Contact Information**

**Dave McGuigan**

Stemmedica Cell Technologies Inc

<http://www.stemmedica.com>

858 685 0910

### **Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **Exiqon Announces 2009 North American Grant Award Winners**

*Exiqon A/S (NASDAQ OMX Copenhagen: "EXQ") today announced the two winners of their 2009 North American Grant Program. Exiqon had recently announced the development of a new research grant program, open to researchers from academic and non-profit institutions across North America, engaged in microRNA research.*

(PRWEB) July 1, 2009 -- Exiqon A/S (NASDAQ OMX Copenhagen: "EXQ") today announced the two winners of their 2009 North American Grant Program. Exiqon had recently announced the development of a new research grant program, open to researchers from academic and non-profit institutions across North America, engaged in microRNA research.

The 2009 Grant Program winners are: Dr. Liang Zhang, Ph.D., of the Rockefeller University Fuchs Laboratory of Mammalian Cell Biology and Development, and Dr. Toshifumi Sugatani, Ph.D., of the Hruska Laboratory in the Department of Pediatric Research at the Washington University in St. Louis School of Medicine.

Dr. Sugatani will receive funding to pursue research aimed at elucidating the role of microRNAs (miRNAs) in physiological and pathophysiological bone remodeling in vivo. This research has potential therapeutic indications for the treatment of osteoporosis, a disease which currently affects more than 75 million individuals worldwide.

Dr. Zhang will receive funding to pursue research aimed at determining how microRNAs (miRNAs) regulate the maintenance and development of epidermal stem cell populations. This research has implications for a wide range of disorders and conditions, including skin cancer. Skin cancer is the most prevalent form of cancer, with over 1 million new diagnoses each year in the United States alone.

To qualify for the grant awards, Dr. Zhang and Dr. Sugatani each submitted abstracts providing background on their field of study, specific aims of the project, as well as detailed experimental plans, including how each would implement research tools from Exiqon. The two winners were faced with strong competition. Submission statistics for the grant program, divulged by Exiqon, revealed a significant response from the research community at large, including nearly 200 informational requests, and more than 90 qualified applications received as of June 15th, the program's deadline.

"The level of response we have received to this program has, quite frankly, exceeded our initial expectations," said Chris Harbert, Director of Marketing, Exiqon North American Life Sciences. "The range of pathologies indicated in the pool of applications clearly illustrates the importance of microRNA investigation in current biomedical research, and reaffirms the strong need for available tools and funding opportunities in this field. We are very proud to help support Dr. Zhang and Dr. Sugatani seek new breakthroughs in microRNA research. It will be exciting to see what unfolds."

The two award winners will split the grant program seed funding of \$25,000. Both grant finalists may use Exiqon Grant Program awards for the purchase of any Exiqon microRNA product or service. Exiqon offers a



complete product line for microRNA investigation, including products for RNA isolation, Microarray analysis, qRT-PCR analysis, Northern Blotting, In Situ Hybridization, and Knockdown studies. Exiqon also offers microRNA profiling services for both microarray and qRT-PCR analysis, complete with full sample QC and customized data analysis and reporting.

Additional information:

Additional information is available through Exiqon representatives located across North America. Interested parties are invited to contact Exiqon at 1-888-647-2879.

Information is also available from these web pages:

Fuchs Laboratory of Mammalian Cell Biology & Development

<http://www.rockefeller.edu/labheads/fuchs/intro.php>

Hruska Laboratory of Pediatric Research

[http://research.peds.wustl.edu/labs/hruska\\_keith\\_a/Home/tabid/545/Default.aspx](http://research.peds.wustl.edu/labs/hruska_keith_a/Home/tabid/545/Default.aspx)

Exiqon

[www.exiqon.com/ls](http://www.exiqon.com/ls)

About Exiqon:

Exiqon is dedicated to making the discovery, development, and application of medicines better, safer and more cost-effective by way of research and diagnostic tests that can identify the treatment needs of specific patient populations.

Exiqon provides research and diagnostic products and services for the analysis of microRNA molecules in a wide variety of disease models and pathologies. Our goal is to help enable groundbreaking discoveries in academic, biotech and pharmaceutical organizations worldwide, who work at the forefront of modern medicine.

Exiqon has more than 200 employees and is listed on the NASDAQ OMX in Copenhagen and categorized as a biotech company (Small Cap+).

Exiqon is financed until expected breakeven in 2011.

###



### **Contact Information**

**Chris Harbert**

Exiqon, Inc.

<http://www.exiqon.com/ls/grants>

1-888-647-2879

### **Online Web 2.0 Version**

You can read the online version of this press release [here](#).

## New PICC Mimics Nature

*A novel coating being used on a new peripherally inserted central catheter (PICC) from r4 Vascular mimics the cell layer found on natural tissue surfaces. r4 Vascular designed the catheter to have a biomimetic surface that mimics the natural glycocalyx layer on endothelial tissues.*

Maple Grove, MN (Vocus) July 1, 2009 -- A novel [coating](#) being used on a new peripherally inserted central [catheter](#) (PICC) from r4 Vascular mimics the cell layer found on natural tissue surfaces. r4 Vascular designed the catheter to have a biomimetic surface that mimics the natural glycocalyx layer on endothelial tissues. Laboratory tests prove that mimicking the glycocalyx layer can dramatically reduce thrombus formation on the catheter surfaces.

r4 Vascular recently gained FDA clearance to launch their first catheter based on this Biomimetic technology. It will be available beginning June 30, 2009 as the Zeus™ Coated CT PICC.

According to Gail Sansivero, MS, ANP, Vascular and Interventional Radiology Nurse Practitioner, Albany Medical Center, "Thrombus can be a real problem for patients with PICCs. Biologically, a patient responds to a catheter insertion within 24 hours by developing bio-film. Thrombus can later amass on the catheter surface, within the catheter and/or become adherent to the vein. The thrombus can cause catheter occlusion, serve as a nidus for infection, and even dislodge into the bloodstream, putting patients at risk for deep vein thrombosis (DVT) or pulmonary embolism (PE)."

Today, clinicians typically try to avoid thrombus occlusion by instilling heparin into catheters between uses. However, many patients are allergic to heparin, which can cause heparin-induced thrombocytopenia (HIT). Some PICC manufacturers have addressed the thrombus problem by affixing valves to their catheters, which can limit placement methods and reliable blood sample withdrawal through the catheter. r4 Vascular engineers took a cue from stealth technologies instead, approaching the problem by camouflaging the catheter in a Biomimetic coating. Laboratory testing has shown the coating to be so effective that it is the first nonvalved PICC to receive FDA clearance for saline-only maintenance.

According to [r4 Vascular's CEO, Michael Sarajian](#), "In speaking with PICC clinicians, we learned that valved PICCs can be difficult to place and unreliable in use. By approaching the thrombus problem scientifically, r4 has developed a nonvalved PICC that enables over-the-wire placement and reliable blood draws while reducing thrombus formation for a longer service life."

r4 Vascular is a privately-held vascular access company driving innovation in vascular access medical technology. r4's passion is "uncomplicating" venous access, chemotherapy, and drug delivery, through product improvements that help catheters remain patent and effective, with reduced risk of complications.

John Zawacki



r4 Vascular, Inc.  
763-494-8400  
Fax: 763-494-8484  
[www.r4vascular.com](http://www.r4vascular.com)

###

**Contact Information****John Zawacki**

r4 Vascular, Inc.

<http://www.r4vascular.com>

763-494-8400

**Online Web 2.0 Version**You can read the online version of this press release [here](#).



## **Therapure Biopharma Inc. Completes Successful Health Canada Facility Inspection**

*Therapure Biopharma Inc., a contract development and manufacturing organization, has completed a Good Manufacturing Practices inspection with Health Canada. As a result of the inspection, Health Canada has issued a compliant rating for the Company. Therapure Biopharma expects to receive an Establishment License in due course. Completion of the Health Canada inspection is a major milestone for the Company.*

Toronto, ON (PRWEB) July 1, 2009 -- Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced that the Company has received a compliant rating from the Health Products and Food Branch Inspectorate of Health Canada.

The rating results from a Good Manufacturing Practices (GMP) inspection conducted at the Company's Meadowpine facility between May 19 and June 12, 2009. The compliant rating means that the Company has demonstrated that the aseptic fill/finish activities conducted in the facility and the associated support services are in compliance with the Canadian Food and Drugs Act and its associated regulations. Based on the results of the inspection, Therapure Biopharma expects to be issued an Establishment License for the Meadowpine facility.

In addition to being recognized in Canada, under the terms of the Mutual Recognition Agreements between Canada and the European Community and Australia, this Establishment License will be recognized by the European Medicines Agency (the EMEA) and the Australian Therapeutic Goods Administration.

"The completion of the Health Canada inspection and the issuance of a compliant rating are major milestones for Therapure Biopharma," said Thomas Wellner. "We have been focused on achieving GMP standards in our facility since acquiring these assets in 2007. Therapure Biopharma staff have devoted their energies to achieving the highest standards of quality, and it has paid off."

GMP standards are the benchmark that must be applied by all manufacturers of approved biopharmaceuticals. As a result of achieving the compliant rating, Therapure Biopharma will be licensed to provide formulation, filling, packaging, and testing services for approved biotherapeutic, Schedule F prescription pharmaceutical, and plasma-derived biological products.

About Therapure Biopharma:

Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. Therapure Biopharma is also a specialist in the development of therapeutics derived from a wide range of biological sources, including hemoglobin, a blood protein. As a contract development and manufacturing organization (CDMO), Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.

For more information, please visit: [www.therapurebio.com](http://www.therapurebio.com)



###

**Contact Information****Thomas Wellner**

Therapure Biopharma Inc.

<http://www.therapurebio.com>

905-286-6204

**Online Web 2.0 Version**You can read the online version of this press release [here](#).



## **Global Prescription Drugs Market to Cross \$897 Billion by 2015, According to New Report by Global Industry Analysts, Inc.**

*GIA announces the release of a comprehensive global report on Prescription Drugs market. The global prescription drugs market is witnessing a significant deceleration in growth. Key factors slowing down growth in the global prescription drugs market include economic downturn, increasing number of drugs going off patent, increasing proliferation of generics, falling drug costs, and fewer new drug approvals. On the positive side, the market is experiencing increased demand for biologics, biopharmaceuticals, and pharmacogenomics, which are spearheading growth in the industry.*

San Jose, CA (PRWEB) June 30, 2009 -- Global [Prescription Drugs](#) market is projected to cross US\$897 billion by 2015. The pharmaceutical industry is also witnessing the effects of the global economic downturn. Various governments worldwide are embarking on cost containment measures, resulting in increased pricing pressures. However, compared to any other industry, the pharmaceutical industry is relatively shielded from economic cycles, as consumer spending on drugs is out of compulsion rather than discretionary spending as in most other industries. As such, sales of pharmaceuticals are expected to slowdown in 2009 and 2010, with declines or flat growth expected in mature markets such as the US, Japan, and Western Europe. The effects of the global economic downturn are expected to vary in different markets owing to the differences in respective market characteristics.

The global prescription drugs market is currently witnessing, and would further witness, a shift in terms of market growth from matured markets towards emerging markets. Patent expiries of major drugs, and subsequent entry of generics that are priced lower, increasing pressure to contain costs, along with increased healthcare legislation and safety scrutiny are slowing down growth in major markets. On the other hand, improved access to innovative and generic medicines, as a result of growth and geographical expansion in primary care, and growing popularity of private health insurance is driving growth in emerging markets such as Brazil, Russia, India, China, South Korea, Mexico and Turkey.

The United States represents the largest market for prescription drugs worldwide. Asia-Pacific region is expected to offer the highest growth potential for prescription drugs over the period 2006-2015. [Oncologics/Cancer Drugs](#) market is the largest and the fastest growing prescription drug therapeutic class. [Respiratory Agents](#) market represents the second largest therapeutic class in 2009, followed closely by [Lipid Regulators](#) market. However, owing to a spate of patent expiries, including that of Lipitor - the largest selling drug, lipid regulators are expected to witness a decline in revenues, and share of the global prescription drugs market.

These and other market data and trends are presented in "Prescription Drugs: A Global Strategic Business Report" announced by Global Industry Analysts, Inc. This GIA report discusses the prevailing trends, issues, demand forecasts, and activities that affect the industry. Detailed discussions on leading drugs by therapeutic class, patent expiries of major drugs, review of pipeline drugs, and M&A activity in the industry give a holistic view of the global and regional prescription drugs markets. The global prescription drugs market is analyzed by revenues in US\$ Billion. The global market is analyzed further by the following therapeutic classes/ categories - Oncologics/ Cancer Drugs, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics,



Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents, and Others. Major regional markets analyzed in the report include USA, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Analytics for the period 2006-2015 provide a comprehensive understanding of the market. Additionally, historic review is provided for the period 2001 to 2005.

Global players profiled in the report include Pfizer, Glaxosmithkline, Novartis, Sanofi-Aventis, Astrazeneca, Roche, Johnson & Johnson, Merck & Co., Abbott, Eli Lilly, Amgen, Wyeth, Teva, Bayer, Takeda, and others. The study enumerates recent developments, mergers, acquisitions, and other strategic industry activities, and is an easy guide to What, Why, When, How, Where, and Who of the industry.

For more details about this comprehensive market research report, please visit - [http://www.strategyr.com/Prescription\\_Drugs\\_Market\\_Report.asp](http://www.strategyr.com/Prescription_Drugs_Market_Report.asp)

About Global Industry Analysts, Inc.

[Global Industry Analysts, Inc., \(GIA\)](#) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone 408-528-9966

Fax 408-528-9977

Email press (at) StrategyR (dot) com

Web Site <http://www.StrategyR.com/>

###



**Contact Information**

**Public Relations**

Global Industry Analysts, Inc.

<http://www.StrategyR.com/>

(408) 528-9966

**Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **Global Small Molecule Kinase Inhibitors Market to Reach \$16.2 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.**

*GIA announces the release of a comprehensive global report on Small Molecule Kinase Inhibitors market. World market for small molecule kinase inhibitor drugs is projected to reach \$16.2 billion by the year 2015. This is primarily driven by the rising interest over the potential of kinase inhibitors in effectively blocking, and modifying protein kinase triggered tumor cell metabolism, proliferation, and DNA damage. Strong growth in the future will be led by expansion of treatment indications in both oncology, and non-oncology disease areas.*

San Jose, CA (PRWEB) June 30, 2009 -- With over 500 identified types of kinase proteins in the human body, its little surprise that these enzymes continue to remain important drug targets for major pharmaceutical drug developers, especially in the oncology space. Given their role in effectively disrupting cell signal pathways, kinase inhibitors are of special interest in the treatment of cancer. The unprecedented success witnessed in patient outcomes with the use of currently commercialized kinase inhibitors, such as, imatinib, among others, has ignited excitement over the untapped potential of this very potent class of drugs. Rising incidences of cancer, and the yet unmet treatment needs offer a strong business case for kinase inhibitors.

The upcoming years are forecast to witness both the strong growth for multi-targeted kinase inhibitors, and the rising popularity of combination drug therapies. Growing incidences of tumor cell resistance to single targeted kinase inhibitor drugs is fingered as the key reason triggering interest in both combination drug therapies, and multi-targeted kinase inhibitors. For instance, growing incidences of resistance to Gleevec, has turned the spotlight on Nexavar, and Sutent, given the potential of these new drugs to offer the much awaited solution to the treatment impasse hitherto encountered. The [multi-targeted kinase inhibitors market](#) is expected to benefit from the growing acceptance of the undisputable fact that the battle against cancer can be horned not by blocking out tumor cells at one point, but by simultaneously blocking multiple biological triggers and pathways, given the tendency of these cells to regroup to recalibrate and spread through new growth paths.

Global sales of [Gleevec](#) are projected to steadily increase between the period 2010 and 2015, as stated by the new market research report. New generation kinase inhibitor drugs like [Nexavar](#) are forecast to witness robust growth over the period 2006 through 2015.

Leading players operating in the marketplace include Amgen Inc, Novartis, AstraZeneca plc, Genentech, Roche, OSI Pharmaceuticals, Pfizer, Bristol-Myers Squibb, Glaxo SmithKline, Wyeth, Onyx Pharmaceuticals Inc., Merck & Co. Inc, KAI Pharmaceuticals Inc, Celgene Corporation, Sanofi-Aventis, and Bayer Schering Pharma AG, among others.

The report titled "Small Molecule Kinase Inhibitors: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of industry overview, technology, trends, growth drivers, challenges, and most promising drugs in pipeline. Also provided are profiles of major players, and an enumeration of recent developments, mergers, acquisitions, and other strategic industry activities. Global small molecule kinase inhibitors market is analyzed by sales in US\$ billion of major drug brands, such as, Gleevec/Glivec, Tarceva, Sutent, Nexavar, Sprycel, Iressa, and Tykerb/Tyverb, among others.



For more details about this comprehensive market research report, please visit -  
[http://www.strategyr.com/Small\\_Molecule\\_Kinase\\_Inhibitors\\_Market\\_Report.asp](http://www.strategyr.com/Small_Molecule_Kinase_Inhibitors_Market_Report.asp)

About Global Industry Analysts, Inc.

[Global Industry Analysts, Inc., \(GIA\)](#) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone 408-528-9966

Fax 408-528-9977

Email [press \(at\) StrategyR \(dot\) com](mailto:press@StrategyR.com)

Web Site <http://www.StrategyR.com/>

###



**Contact Information**

**Public Relations**

Global Industry Analysts, Inc.

<http://www.StrategyR.com/>

(408) 528-9966

**Online Web 2.0 Version**

You can read the online version of this press release [here](#).

## Asia Debut for Money-Saving Pharma-Packaging Machines from Ireland

*The Northern Irish packaging machinery manufacturer, Sepha Ltd. is breaking into one of the world's largest pharmaceutical markets, Japan, by showcasing its money-saving, [leak testing](#) and [de-blistering](#) machines for the first time there at the world's largest pharmaceutical event in Tokyo on 1-3 July. Ahead of its presence at Interphex, Sepha has already received very positive feedback from Japanese pharmaceutical manufacturers during a fact-finding mission and believe it is the right time to forge ahead with its presence there.*

(Vocus) June 30, 2009 -- The Northern Irish packaging machinery manufacturer, Sepha Ltd. is breaking into one of the world's largest pharmaceutical markets, Japan, by showcasing its money-saving, [leak testing](#) and [de-blistering](#) machines there for the first time at the world's largest pharmaceutical event in Tokyo on 1-3 July. Ahead of its presence at Interphex, Sepha has already received very positive feedback from Japanese pharmaceutical manufacturers during a fact-finding mission and believe it is the right time to forge ahead with its presence there.

Sepha CEO Aubrey Sayers explains: "As the economic downturn forces global consolidation of the pharmaceutical industry and puts the focus on projects that achieve cost savings and a quick return in investment, we believe the time is right to introduce BlisterScan in Asia. This is an innovative [leak-testing](#) machine that tests for leaks in blister-packs of drugs without the need for pack disposal after testing. This reduces waste and saves the pharmaceutical company time and money - factors that are becoming increasingly important within the pharmaceutical industry. We have something unique to offer and Interphex is the ideal opportunity for people to see it in action."

BlisterScan can detect and locate leaks as small as 7 microns across a full cross-section of the entire blister web. Blister packs are scanned by a beam of light both before and after a vacuum is applied. The difference between these scan readings is used to calculate the size of the hole in the blister pack. It identifies the precise pocket which leaks - ideal for testing alongside blister lines to speed up diagnosis of any problems and preventing the production of excess rejects. It is a non-destructive, clean, dry process so any packs that pass the test can be returned to the production line. Packs that fail the test can have the contents removed for repackaging using one of Sepha's [de-blistering](#) machines. The alternative Methylene blue dye test by comparison renders any tested blister packs unsaleable.

Operators have no influence over the results of the BlisterScan test as the Pass or Fail status of each pocket is shown on the screen, and can be printed out or saved. BlisterScan can be fully validated, unlike the Blue Dye test where operator has to make a subjective decision whether a pack passes or fails.

Sepha will also be introducing Press-Out Manual Wide -- a small, portable, manual [de-blistering](#) machine that is suitable for in-line and diagonal push-through blister packs. It does not have any tooling to change over and only takes about 3 minutes to set up for a new blister pack. It can de-blister up to 20 packs per minute and is operated manually by a handle.



Background Information about Sepha Ltd:

Sepha is a specialist manufacturer of non-destructive inspection equipment for inspecting the seal integrity of pharmaceutical and medical device blister packs. Sepha also designs and manufactures a range of deblistering equipment for product recovery from pharmaceutical blisters and lab-scale blister packing machines for clinical trial use. For further information see [www.sepha.com](http://www.sepha.com)

###

**Contact Information**

**gillian.parker**

Sepha Ltd.

<http://www.sepha.com>

++44(0)28 90484848

**Online Web 2.0 Version**

You can read the online version of this press release [here](#).

**News Image**





## **New Book on Halal Food and the Modern Food Supply Chain is Being Released in June 2009**

*Understanding the Halal Food Supply Chain is a much awaited book authored by Dr Azhar Lodhi, an independent food research consultant, based in the UK. It provides information and promotes discussion on issues relevant to consumers of halal food, food technologists, food researchers and industry.*

London, UK (PRWeb UK) June 28, 2009 -- HFRC UK Limited, a London consultancy company involved in research, training and management in the halal food industry, is publishing 'Understanding the Halal Food Supply Chain' authored by Dr Azhar Lodhi (<http://www.hfrcuk.net>).

The food supply chain is changing from a local business to a global venture due to rapid developments in food technology, food transportation and food trade. Halal food emerged as a serious international business opportunity due to an increase in demand by almost 2 billion Muslim consumers.

'Understanding the Halal Food Supply Chain' discusses issues pertaining to halal food in the context of the modern food industry and commerce. The book covers all stages from farm to fork and presents issues relevant to the halal food supply chain using an innovative and accessible approach. It also discusses the necessity of integrated approaches and frameworks to develop a global halal food supply chain.

This book is a useful starting point for research scientists, food technologists, religious scholars, and consumers. It is also aimed at food industry entrepreneurs wanting to develop niche halal food products and services.

Dr Lodhi's extensive work experience in food research, science & technology, within industry and academic environments provided an insight to the major issues faced by the global halal food supply chain. His personal experience of living both in Muslim and secular countries contributed to a broader view of the challenges faced by halal food consumers.

For additional information on 'Understanding Halal Food Supply Chain', or for a copy, please contact HFRC UK or visit [www.hfrcuk.net](http://www.hfrcuk.net).

Contact:

HFRC UK LIMITED

Suite B

29 Harley Street London W1G 9QR

Tel: 02070162189

Fax: 02071827088

<http://www.hfrcuk.net>

###



### **Contact Information**

**Maria Pinto**

HFRC UK Ltd

<http://www.hfrcuk.net>

+44 (0)20 7016 2189

### **Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **MEDS World, LLC Provides Multiple Environments with Designed Solutions - Wherever People Congregate, MEDS Odor Elimination Solutions Offer Eco-Friendly, Odor-Free Air**

*In 2008, Bruce Hecht and Chase Walker formed MEDS World, LLC, launching innovative odor elimination, exterior plastic trim and headlight restoration products to the Automotive, RV and Marine industries. Bruce and Chase have combined over fifty years of management experiences, in a myriad of industries, to introduce these innovative and eco-friendly products to the pan-national marketplace. You can find us here: <http://www.meds-world.com>*

Suwanee, GA (PRWEB) June 28, 2009 -- MEDS offers multiple, scalable delivery solutions for permanent odor elimination. SNAP is a silicone free, easy to use solution for permanent exterior plastic trim restoration. RESTOREM permanently rejuvenates oxidized headlight lenses in less than 10 minutes. The MEDS automotive line of solutions increase billable services per vehicle, save time and bring increased profits to the bottom line for after-market car-care technicians and automotive detailers.

Dealerships may elect to bring these solutions in-house, adding revenues to the service drive. Ease of use and minimal training make MEDS products an attractive and inexpensive alternative to improve CSI. All MEDS automotive solutions have been approved by a leading Fortune 500 company for use in nationally franchised automotive dealerships.

In 2009, the MEDS deodorization solutions were introduced to hotels, law enforcement agencies and assisted living facilities. Our patented and scalable delivery systems have been approved and recommended by the EPA, OSHA, FDA and UK governmental agencies as effective and environmentally friendly odor elimination processes. The release of our EPA registered active-oxidant eliminates the bacterial source of odors. NSF Certified, for use in restaurants, MEDS solutions offer clean air in walk-ins and keep refrigeration units odor free. BLAST, FIBER FRESH and MAINTENANCE odor elimination systems are NOT a mask and provide permanent solutions to odors caused by smoke, mold, mildew, pets and humans.

Hotels enjoy fast acting MEDS deodorization processes, allowing guest rooms to be turned and sold between check-out and check-in times. MEDS products offer "whole house" solutions to odor remediation for the hospitality industry. From check-in to check-out, from the front of the house to the back of the house, housekeeping and maintenance departments all benefit from the MEDS solutions to every day challenges.

Law enforcement and EMS personnel reduce health risks with the by-product of our active-oxidant, known to eliminate hazardous and toxic bacteria. In a locker room study of a major University, MEDS products reduced upper respiratory infections by twenty-five percent. The active-oxidant in MEDS is similar to the anti-microbial used to eliminate Anthrax spores in the Hart Senate Building in 2001 and the U.S. Post Office in Boca Raton, Florida.

<http://www.epa.gov/pesticides/factsheets/chemicals/chlorinedioxidefactsheet.htm>

MEDS deodorization solutions are perfectly suited to maintain an odor free environment in assisted living facilities. MEDS scalable delivery system keeps curtains, upholstery, linens and bath areas odor free. MEDS



deodorization products have effectively eliminated methamphetamine residue from a "meth lab" in Western North Carolina

These are only a small sample of solutions MEDS provide for multiple environments. When your company is ready to examine our proven solutions for odor remediation, exterior plastic trim restoration and rejuvenating oxidized headlights, please contact us.

In the United States, our toll free number is 877-886-8727

Outside of the US, please call 828.712.3130

###



### **Contact Information**

**Chase Walker**

MEDS World, LLC

<http://www.meds-world.com>

877-886-8727

### **Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **METTLER TOLEDO is Pleased to Launch Version 2.0 of its LiQC Multi-parameter System for Simultaneous Determination of Density, Refractive Index, pH/conductivity and Color**

*LiQC increases productivity by combining single measurements into one fully automated process. A sample is filled into a sample vial, placed onto an automatic sample changer, and assigned a barcode label. LiQC automatically completes every subsequent step: choosing the appropriate method, pumping the sample into the various flow-through cells, and performing all measurements. The results are statistically evaluated, compared to specifications and transferred to LIMS systems. LiQC thoroughly cleans and dries the measuring cells simultaneously before moving on to the next sample.*

Columbus, Ohio (PRWEB) June 28, 2009 -- METTLER TOLEDO is pleased to launch version 2.0 of its LiQC multi-parameter system for simultaneous determination of density, refractive index, pH/conductivity and color.

### Measurement Principle

LiQC increases productivity by combining single measurements into one fully automated process. A sample is filled into a sample vial, placed onto an automatic sample changer, and assigned a barcode label. LiQC automatically completes every subsequent step: choosing the appropriate method, pumping the sample into the various flow-through cells, and performing all measurements. The results are statistically evaluated, compared to specifications and transferred to LIMS systems. LiQC thoroughly cleans and dries the measuring cells simultaneously before moving on to the next sample.

### Lab Instrument "First" -- Biometric User Identification

Version 2.0 brings additional, exciting benefits: For the first time in analytical instrumentation, biometric user identification with a fingerprint reader greatly facilitates user management, which is a prerequisite for analysis in compliance with 21CFR-11 or ISO17025 standards. Additionally, LiQC now works with stand-alone density and refractometers as well as with the DR combined meters, so the system may be used for density and color measurement of lubricants or for pH and Brix measurement of fruit juice.

LiQC brings substantial time savings, simplified compliance, reduced margin of error and easy LIMS integration for analytical laboratories in many different industries. Its benefits are particularly appreciated within flavor & fragrance, petrochemical, beverage and pharmaceutical industries where multi-parameter measurements are performed for identification, purity and concentration determinations and by independent testing laboratories that have to deal with a large quantity of samples and very short turnaround times.

### About METTLER TOLEDO

METTLER TOLEDO is a leading global manufacturer of precision instruments. The Company is the world's largest manufacturer and marketer of weighing instruments for use in laboratory, industrial and food retailing applications. The Company also holds top-three market positions in several related analytical instruments markets and is a leading provider of automated chemistry systems used in drug and chemical compound discovery and development.



Additional information about METTLER TOLEDO can be found at [www.mt.com](http://www.mt.com).

###



**Contact Information**

**Shana Wheeler**

METTLER TOLEDO

<http://www.mt.com/LIQC>

614-438-4936

**Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **The Korean Biopharma Industry and Market Overview in New York Pharma Forum**

*The New York Pharma Forum will present Korean biopharma industry and market overview in June 30 2009. The New York Pharma Forum provides a vehicle for dialogue among U.S and Japanese biopharmaceutical executives and business and financial professionals on global issues of common interest. The New York Pharma Forum chose Korean biopharma market issue this time based on growing interest for Korean biopharma market.*

New York, NY (PRWEB) June 27, 2009 -- The New York Pharma Forum will present Korean biopharma industry and market overview in June 30 2009. The New York Pharma Forum provides a vehicle for dialogue among U.S and Japanese biopharmaceutical executives and business and financial professionals on global issues of common interest. The New York Pharma Forum chose Korean biopharma market issue this time based on growing interest for Korean biopharma market.

With a population approaching 50 million and overall GDP estimated at \$1.278 trillion in 2008, South Korea ranks as one of the world's leading economies today. The country ranks 11th in the global pharmaceutical market by size, and the market is expected to grow to \$15.6 billion by 2013. South Korea has approximately 570 pharmaceutical manufacturers. Korean government injects around one billion dollars over ten years to boost the Korean pharmaceutical industry, with over 80 percent of the total earmarked for R&D. Korea has made dramatic advances recently in clinical trials as well.

This program will feature presentations by experts representing the Korean biopharmaceutical industry who will provide a comprehensive overview of the country's healthcare system, biopharma industry, and business opportunities. Speakers will provide a wide range of information from therapeutic markets to profiles of the major players, regulatory and policy related issues, and intellectual property rights.

In addition, KHIDI (Korea Health Industry Development Institute) which is Korean Ministry of Health agency will hand out a directory book of Korean major pharmaceutical companies. The directory book includes the list of 100 major players of Korea with their amount of sales, revenue, major therapeutic area, and contact information. Directory book also contains teaser memorandum(TM)s of 27 state-of-the-art biotechnologies which are available to be licensed out.

The New York Pharma Forum featuring Korean biopharma industry overview will be held at the Nippon Club located in 145 West 57th Street New York City. To attend the forum, visit [www.nypharmaforum.org](http://www.nypharmaforum.org).

###



### **Contact Information**

**Minhye Park**

KHIDI

<http://www.nypharmaforum.org/index.php?s=events&item=143>

212.826.0900

### **Online Web 2.0 Version**

You can read the online version of this press release [here](#).

## DuPont Adds Cotton to India Seed Product Lineup

### *Strengthens Growing Seed Business in India*

Hyderabad, India (Vocus) June 25, 2009 -- [DuPont](#) today announced it has made two cotton acquisitions in India to enhance its product lineup and strengthen its growing business here. DuPont business [Pioneer Hi-Bred](#) has purchased the cotton seed business of Nandi Seeds, based in Mehboob Nagar, Andhra Pradesh, India, and acquired cotton germplasm from Nagarjuna Seeds, based in Secunderabad, Andhra Pradesh, India.

“These acquisitions will help us enter the cotton seed market here and meet the needs of Indian farmers who grow more than 9 million hectares of cotton each year – more than anywhere else in the world,” said K.V. Subbarao, country manager -- Pioneer India. “Cotton is a natural fit for Pioneer in India. It completes our high-value product and service offering to farmers and enables us to further strengthen our growing seed business here.”

Pioneer currently offers corn, rice, pearl millet, sunflower and mustard in the Indian market and has grown revenue 40 percent annually for the last five years to reach about \$70 million in 2008.

“Agriculture, food and nutrition is a key growth segment for DuPont in India, and these acquisitions are part of the company’s strategy to expand its presence here,” said [Balvinder S. Kalsi](#), president -- [DuPont India](#). “We are positioning our market-driven science company to grow at a faster pace by leveraging opportunities that will enable us to contribute to India’s sustainable economic development.”

This is the latest in a series of investments by DuPont in India. Pioneer recently announced the opening of a new corn research center in Bangalore to speed delivery of new, improved products to market and meet the growing demand for food and feed. The new Bangalore center is the fifth field research facility in India for Pioneer and will develop high-yielding hybrids adapted to the unique growing conditions in the area. DuPont has significantly increased its seed research investment in India in 2008 and has increased capacity for product development and evaluation across the country.

DuPont also recently established the DuPont Knowledge Center (DKC) in Hyderabad, India, which includes the Biotechnology Research Center, a key location for global biotech research. This biotech center is the first integrated agriculture and industrial biotechnology research center for DuPont outside the United States, and is one of five global agricultural biotech research facilities where DuPont conducts biotech discovery work. The other research facilities are in Wilmington, Del., U.S.; Johnston, Iowa, U.S.; Redwood City, Calif., U.S.; and Beijing, China.

Pioneer has been selling hybrid seed in India for more than 30 years and is one of the nation’s leading suppliers of improved seed genetics. Pioneer supports the sale of its products to more than 1.5 million customers in India with an extensive sales and agronomy team that works closely with Indian farmers to get the right product on the right hectare to maximize their productivity and profitability.



Pioneer Hi-Bred, a DuPont business, is the world's leading source of customized solutions for farmers, livestock producers and grain and oilseed processors. With headquarters in Des Moines, Iowa, Pioneer provides access to advanced plant genetics in nearly 70 countries.

DuPont India is a subsidiary of DuPont. The DuPont association with India extends back more than 200 years, since the first shipment of raw materials for black powder for explosives was imported from India into the United States in 1802. Today, DuPont India, with more than 1,000 employees, markets a wide range of products in various market segments. The company has six production facilities in India in three locations for DuPont Crop Protection, DuPont Engineering Polymers, DuPont Refinish, and Pioneer® hybrid seeds.

DuPont is a science-based products and services company. Founded in 1802, DuPont puts science to work by creating sustainable solutions essential to a better, safer, healthier life for people everywhere. Operating in more than 70 countries, DuPont offers a wide range of innovative products and services for markets including agriculture and food; building and construction; communications; and transportation.

**Forward-Looking Statements:** This news release contains forward-looking statements based on management's current expectations, estimates and projections. The company does not undertake to update any forward-looking statements as a result of future developments or new information. All statements that address expectations or projections about the future, including statements about the company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects," "anticipates," "plans," "intends," "projects," "indicates," and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in DuPont's filings with the Securities and Exchange Commission, particularly its latest annual report on Form 10-K, as well as others, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions of countries in which the company does business; competitive pressures; successful integration of structural changes, including acquisitions, divestitures and alliances; research and development of new products, including regulatory approval and market acceptance, and seasonality of sales of agricultural products.

The DuPont Oval Logo, DuPont™, The miracles of science™ and Pioneer® are registered trademarks or trademarks of DuPont or its affiliates.

###



### **Contact Information**

**Krishnakoli Dutta**

DuPont

<http://www.pioneer.com/>

+91-124-509-5004

### **Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **CSOFT Announces Introduction of L10NPRO 3.0 at 6th Annual Worldwide Summit in Beijing**

*Cutting Edge System Will Offer Clients Customized Solutions to Complex Localization Needs*

Beijing, China (PRWEB) June 26, 2009 -- [CSOFT International](#) Ltd., a leading provider of multilingual localization, [testing](#), and [outsourced software development](#) for the global market, announced the upcoming launch of L10NPRO 3.0 at its 6th Annual Worldwide Operations Summit in Beijing, China. L10NPRO 3.0, scheduled for release this fall, is designed to be a practical, no hassle [localization](#) management enterprise system that incorporates all areas of a typical localization workflow, such as quotation, TM leverage, project tracking, review, delivery and invoicing.

"CSOFT's L10NPRO will offer streamlined solutions for every day localization challenges," said Shunee Yee, CEO of CSOFT International, Ltd. "L10NPRO is highly automated and straightforward to use so it will be much more nimble than other similar systems."

One of the important features of CSOFT's L10NPRO is the Engineering Memory (EM) and the ability for the system to "learn" in order to process various file formats. EM is a cutting-edge technology developed within CSOFT that borrows the concept of [Translation Memory](#) (TM) technology. EM will provide engineers with the ability to reuse previous engineering work performed for the same file type, dramatically improving file preparation efficiency and consistency. The other important feature is L10NPRO's EM Editor to edit once a new file type is processed so that the system can automatically process files with the same format thereafter.

L10NPRO's customizable and straightforward Web 2.0 interface will allow companies to experience immediate localization [productivity gains](#) with ease from their own web browser. Unlike other systems on the market that were developed exclusively by technical engineers, CSOFT's L10NPRO is the collaboration between its project managers and L10N engineers. CSOFT's project teams have been using L10NPRO to manage localization projects internally for years, which is how it is able to seamlessly adapt its workflow in this practical manner. The system is now being released externally to offer true savings for clients, and the client will not have to worry about hidden costs, maintenance, learning curves, or constant upgrades. The client gets all the management help with a simple click of the mouse.

"Competitors require customers to make significant capital investments - often in excess of \$200,000 USD plus expensive yearly maintenance fees," continued Yee. "CSOFT is revolutionizing the TMS space by offering the use of L10NPRO for free so our customers can save significant costs. Entrepreneurial thinking is the catalyst for evolution and the launch of L10NPRO 3.0 is yet another example of how CSOFT is the industry leader in providing creative solutions. By putting our clients first, we are also hoping to enhance our services for them and improve efficiency."

In addition to announcing the fall launch of L10NPRO at this year's Worldwide Summit, CSOFT also brought in industry experts from Beckman Coulter, Inc., Microsoft, Lavasoft and Common Sense Advisory to address its

worldwide team.

"Hosting such events where a diverse group of people, internal employees as well as [external clients](#) and experts, can gather for further knowledge within the industry is one way CSOFT hopes to distinguish itself within the industry," continued Yee.

Tammy Werner of Beckman Coulter addressed the entire company on the "Unique Challenges with Medical Device Translation and Localization." Ben Sargent of Common Sense Advisory discussed "How TMS is changing the landscape of language services." Jason King of Lavasoft led a session on "Global Sales Strategy" to CSOFT's worldwide business development team. Will Knight of Microsoft (China) also met with the team to share marketing strategies and sales alignment to drive growth.

"Information sharing is often confined within certain industries," said Jason King, CEO of Lavasoft. "CSOFT's Worldwide Summit is a great example of partners willing to break through those boundaries, to achieve growth for themselves as well as for those partners around them."

CSOFT has one of the largest technical resources in China with a global network of operations spanning Boston, San Francisco, Japan, Germany, Canada, the UK, and Australia as well as language teams in European and Asian markets. For more information about CSOFT, please visit: <http://www.csoftintl.com>. Media inquiries should be directed to [elena.mccoy\(at\)csoftintl.com](mailto:elena.mccoy@cssoftintl.com) or +1.415.462.5674.

#### About CSOFT

CSOFT International Ltd., is a leading provider of multilingual localization, testing and outsourced software development for the worldwide market. Powered by our expert in-country linguistic resources, CSOFT delivers language translation/technology solutions into 90+ languages. CSOFT services a variety of industries such as information technology, manufacturing, life sciences, financial services, chemical and energy. Using industry best practices and processes, CSOFT streamlines translation and localization for software, product manuals, online help, marketing collaterals and website content, and offers multilingual publishing for virtually all formats.

#### About Beckman Coulter, Inc.

Beckman Coulter, Inc., based in Fullerton, California, is a leading manufacturer of biomedical testing instrument systems, tests and supplies that simplify and automate laboratory processes. Spanning the biomedical testing continuum--from pioneering medical research and clinical trials to laboratory diagnostics and point-of-care testing--Beckman Coulter's 200,000 installed systems provide essential biomedical information to enhance health care around the world. For additional information, please visit [www.beckmancoulter.com](http://www.beckmancoulter.com).

#### About Common Sense Advisory

Common Sense Advisory, Inc. is an independent research and analysis firm specializing in the on- and offline operations driving business globalization, internationalization, translation, and localization . Its research, consulting, and training help organizations improve the quality of global business. For more information about Common Sense Advisory's research, reports, and globalization and localization consulting services visit: <http://www.commonsenseadvisory.com>.



#### About Lavasoft

Founded in 1999, Lavasoft is "the original anti-spyware company", with over 350 million downloads worldwide for the flagship Ad-Aware product. A private company headquartered in Gothenburg, Sweden, Lavasoft provides innovative security solutions for consumer and business channels, including anti-spyware, anti-virus, registry optimization, firewall, digital shredding, and encryption. Lavasoft has a global network of distributors, resellers, and retailers.

#### About Microsoft

Founded in 1975, Microsoft is the worldwide leader in software, services and solutions that help people and businesses realize their full potential.

#### MEDIA CONTACT:

Elena McCoy

[elena.mccoy\(at\)softintl.com](mailto:elena.mccoy@softintl.com)

US Tel.: +1.415.462.5674

China Tel: +86.10.6418.5353

###



**Contact Information**

**Elena McCoy**

CSOFT International Ltd.

<http://csoftintl.com>

1-415-462-5674

**Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **Register to Win a Ski Weekend and Make Your Synthesis Easier with EasyMax™: the First Automated Chemistry Development Tool That Requires No Training**

*EasyMax™ is a small and powerful lab reactor system for the synthesis lab and synthetic organic chemist - heating and cooling without an additional cryostat. For a limited time, METTLER TOLEDO is offering a FREE TRIAL of the first automated chemistry development tool that requires no training, EasyMax™, and the chance to WIN A SKI WEEKEND\* in St. Moritz, Switzerland or Colorado, USA.*

Columbia, MD (PRWEB) June 26, 2009 -- METTLER TOLEDO EasyMax™ is the [next generation jacketed lab reactor for chemical development](#). Due to the implemented technology and wide temperature range of -25°C to 180°C, syntheses at both sub-ambient and elevated temperatures are effortless. The intuitive touch screen operation, accuracy, reproducibility, and simple working procedures make the EasyMax™ the ideal tool for chemical development. This lab reactor lets the organic chemist run synthesis easier, faster, and better.

For a limited time, METTLER TOLEDO is offering a FREE TRIAL of the [first automated chemistry development tool that requires no training, EasyMax™](#), and the chance to WIN A SKI WEEKEND\* in St. Moritz, Switzerland or Colorado, USA.

###

**Contact Information****Patricia Hicks**

Mettler-Toledo AutoChem, Inc.

<http://www.mt.com/easymax4chemists>

410-910-8486

**Online Web 2.0 Version**You can read the online version of this press release [here](#).



## **Industry Leaders Will Gather to Discuss the Future of the "Hydrogen Economy" in Washington DC**

*Over 120 producers, developers and users expected to attend conference Wed. September 30-Friday, October 2, 2009.*

Portland, Maine (PRWEB) June 26, 2009 -- IntertechPira, in conjunction with the National Hydrogen Association, is proud to announce "[Hydrogen Production and Storage 2009](#)," an International conference bringing together hydrogen producers, developers and users to discuss the future of this sustainable industry. The conference will take place from Wednesday, September 30, 2009 - Friday, October 02, 2009 at the Marriott Washington in Washington, DC.

"Hydrogen Production and Storage 2009" will feature presentations from leaders in the industry, including Hydrogen Discoveries, Proton Energy Systems and Nissan, while allowing conferees networking opportunities to discuss the viability and commercial potential of near-term technologies for producing and storing hydrogen, both on a large and a small scale.

"We are excited to work with IntertechPira to highlight the advances in hydrogen storage. With today's hydrogen storage technologies, we can drive cars more than 450 miles on one tank of hydrogen, make power at cell phone towers more reliable and help warehouses save money by switching to fuel cell forklifts," said Jeffrey Serfass, President of the National Hydrogen Association. "And the next hydrogen storage advances will allow products to run longer with less weight and taking up less space. This is an important event to showcase these successes and have frank discussions on what's needed to get hydrogen quickly and efficiently in and out of smaller containers that weigh less."

The conference is designed for business development managers, R&D specialists, technology planners, financial officers, venture capitalists, and investors in the energy production, transmission, conversion, and distribution industries. The conference will also offer opportunities for applications where hydrogen will play a key role, such as transportation, electric power generation and mobile battery-powered devices such as laptop computers and cell phones.

For more information about "Hydrogen Production and Storage 2009" or to attend, visit [www.hydrogenproductionandstorage.com](http://www.hydrogenproductionandstorage.com). For inquiries about possible speaker opportunities, please contact Christine Groff +1 207 781 9617 or [christine.groff@pira-international.com](mailto:christine.groff@pira-international.com).

### **About IntertechPira**

IntertechPira provides events, training, online information and publications across a wide range of niche commodities and disruptive technologies affecting industry. Our 100% independent products are provided globally 24/7 and delivered by teams of independent experts at sites in Portland, Maine, US and London, UK through 20 specialized industrial platforms. Our core competencies are information on: research and product development; globalization and new markets; production methods; regulatory and compliance.



###

### Contact Information

**Joan Woodbrey**

IntertechPira

<http://www.hydrogenproductionandstorage.com>

207 781 9636

### Online Web 2.0 Version

You can read the online version of this press release [here](#).

### News Image





## **World Nanomedicine Market to Cross \$160 Billion by 2015, According to New Report by Global Industry Analysts, Inc.**

*GIA announces the release of a comprehensive global report on Nanomedicine markets. The global Nanomedicine market continues to register robust growth largely fueled by unique properties of nanoparticles that provide novel and improved advantages, introduction of novel products, healthy rise in funding across the globe, and increased hype around nanotechnology.*

San Jose, CA (PRWEB) June 25, 2009 -- Nanomedicine represents a principal domain of nanotechnology that offers capability to significantly change the course of treatment of life-threatening diseases. Unlike other therapies, nanomedicine enhances efficacy and significantly minimizes adversities associated with standard therapeutics. The application of nanotechnology in the form of nanomedicine in areas including nano drug delivery, nanoanalytical contrast reagents, nanobiomaterials, and nanopharmaceuticals has been surging at a stable rate. Recent years saw implementation of several programs by the industry to bridge the gap between outcomes of clinical research and commercial products. As a result, the present nanobiomaterial product pipeline poses a healthy picture with numerous novel products for use in health care applications, primarily in the form of coatings. Further, research and development in the [nanomedicine market](#) is expected to offer several novel products that can effectively improve the health of patients suffering from health disorders and illnesses.

[Drug delivery market](#) represents the largest application area, while the [Biomaterials segment](#) represents the fastest growing application segment for nanomedicine over the years 2006 through 2015.

The nanomedicine market is highly fragmented and is characterized by the presence of several key and niche players. Major market participants in the nanomedicine market include Abraxis BioScience Inc., AMAG Pharmaceuticals Inc, Arrowhead Research Corporation, Crucell N.V., Flamel Technologies S.A., Elan Corporation Plc, Enzon Pharmaceuticals Inc., Life Technologies Corporation, Nanosphere Inc., Nektar Therapeutics, Novavax Inc., Oxonica Plc, Par Pharmaceutical Companies Inc., Starpharma Holdings Limited, and Wyeth Pharmaceuticals Inc., among others.

The report titled "Nanomedicine: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., covers major market dynamics, trends, issues, and competition pertaining to the market. Analytical estimates and projections on market size have been presented in terms of dollar sales over the time period 2006-2015. The report enumerates recent developments, mergers, acquisitions and other strategic industry activities. The study analyzes the nanomedicine market by the following application areas - Drug Delivery, In Vitro Diagnostics, In Vivo Imaging, Biomaterials and Other Applications.

For more details about this comprehensive market research report, please visit - [http://www.strategyr.com/Nanomedicine\\_Market\\_Report.asp](http://www.strategyr.com/Nanomedicine_Market_Report.asp)

About Global Industry Analysts, Inc.

[Global Industry Analysts, Inc., \(GIA\)](#) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year.



Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone 408-528-9966

Fax 408-528-9977

Email press (at) StrategyR (dot) com

Web Site <http://www.StrategyR.com/>

###



**Contact Information**

**Public Relations**

Global Industry Analysts, Inc.

<http://www.StrategyR.com/>

(408) 528-9966

**Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **New Probiotics Bacteria Supplier ProbioFerm, LLC Provides the Highest Quality Beneficial Bacteria Available for Product Development**

*Although recently established, new Probiotics bacteria supplier ProbioFerm, LLC pulls from a thoroughly experienced team to provide the highest possible quality bacteria available. The unique private label manufacturing company serves animal feed and agriculture businesses, functioning as a valuable partner from product development to manufacturing.*

Urbandale, IA (PRWEB) June 25, 2009 -- Created by industry expert Scott Goldsmith, new Probiotics Bacteria Supplier [ProbioFerm, LLC](#) draws upon decades of experience to produce the highest quality beneficial bacteria on the market. ProbioFerm works closely with animal feed and agricultural businesses in order to satisfy client needs from product development to manufacturing and marketing.

ProbioFerm serves as a one-stop manufacturing company. From contract fermentation to developing custom blends of high quality [bacteria concentrates, pastes/gels syringes, water dispersible powders and feed additives](#), ProbioFerm specializes in developing unique packaging and delivery methods that utilize innovative technologies to produce private label finished goods.

The company's state-of-the-art fermentation equipment is able to provide bench top fermentation service and scale up to larger production runs. Their fermentation, separation, and freeze drying equipment all have Cleaning-In-Place (CIP) and Sterilization-In-Place (SIP) capability, ensuring production of the highest quality beneficial bacteria all the time.

ProbioFerm's manufacturing systems are designed with the highest purity standards in mind and implement standard industry practices in order to provide its customers with a supply of high quality cultures. An in-house quality assurance laboratory ensures the quality of all cultures produced.

Recently, consumer awareness has grown rapidly in regards to the health benefits of Probiotics, which has prompted a number of supplement companies to launch their own products into the market. To ensure that client bacteria cultures remain at their highest quality during the shelf life of every product developed, [ProbioFerm](#) provides the highest standard possible in catering every production run.

While other companies provide merely bacteria, ProbioFerm works to uniquely deliver goods and services in a manner that no other contact manufacturing company can. ProbioFerm President Scott Goldsmith has been in the probiotics industry for more than 20 years, providing him with not only necessary know-how but also enabling him to create essential manufacturer-client relationships that serves as the foundation of a successful business. Goldsmith has mastered and will be continuously developing the company's unique approach to creating a committed relationship with valued clients.

With technologically advanced expertise and equipment, ProbioFerm grows most bacteria strains, including both [Probiotic strains and forage preservation bacteria](#), and possesses the capability to incorporate them into a multitude of finished goods packaging. Small business companies are guaranteed to receive professional guidance for their innovations and product development.



#### About ProbioFerm, LLC

ProbioFerm provides all levels of contract fermentation and can provide bulk cultures of various strains of bacteria. The company is experienced in partnering with customers in developing and producing private label finished goods. Other important certifications like Certificates of Analysis are readily provided with their in-house Quality Assurance testing lab. This company aims to deliver all your Probiotic needs from start to finish, ensuring clients receive the highest quality product there is.

For additional information about ProbioFerm, contact us.

ProbioFerm, LLC.

10215 Dennis Dr.

Urbandale, IA 50322

TEL 515-270-5250

FAX 515-270-1091

WEB [www.probioferm.com](http://www.probioferm.com)

###



**Contact Information**

**Scott Goldsmith**

<http://www.probioferm.com/>

515-270-5250

**Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **Zvetco Biometrics Delivers a Cohesive Security System Integrating Fingerprint Biometrics with Sun Identity Management Solutions.**

*Best-in-class fingerprint authentication hardware manufacturer and network security solution provider Zvetco Biometrics today announced that its Verifi™ line of fingerprint biometric readers are now compatible with Sun Microsystems' Identity Management Suite via the integration of BiObex™, a leading biometric middleware from Advanced Biometric Controls.*

Orlando, FL (PRWEB) June 24, 2009 -- This integration enables biometric security to be applied through the web based identity management capabilities available on Sun's Identity Management Suite to provide strong authentication solutions for government and commercial applications. Whether protecting sensitive enterprise applications, meeting the demands of regulatory compliance, or complying with federal mandates, the Zvetco Verifi™ and BiObex™ solution delivers a cohesive system of protection.

"With the simple addition of Zvetco's Verifi fingerprint readers and BiObex middleware to existing users, government and enterprise can realize significantly increased security by verifying the identity of those individuals wishing to access their systems and networks. This first step of applying Zvetco Biometrics readers' to Sun Identity Management Suite will lead the way for integration with Solaris 10, Solaris 10 Trusted Extensions and Sun Ray ultra thin client. Sun Microsystems customers will soon be able to deploy biometric authentication on Sun Rays, take advantage of its "hot-desking" capabilities and use biometrics-based Web Single Sign-on authentication with Sun OpenSSO Enterprise," said Zavi Cohen, CEO, Zvetco Biometrics.

"Advanced Biometric Controls is pleased that Zvetco has selected BiObex for their Verifi suite of fingerprint readers," said Chris Sands, CEO of Advanced Biometric Controls. BiObex software enables organizations to enroll, manage, and apply biometric authentication to security and identification needs. Its core functionality allows an enterprise to define policy-based methods for implementing various types of biometric access control systems, using a consistent application for management, authentication, enrollment, administration, auditing, event logging, and reporting. While interoperability, ease-of-use, and multi-platform versatility are clear advantages of BiObex, the essential customer value is increased security."

The Verifi line of readers, including the P4000 and P5000 family of products are enterprise ready fingerprint readers with all metal housings, optional waterproof capability and extremely high reliability make for the perfect candidates for large-scale enterprise deployments. Additionally, the waterproof capabilities are ideal for healthcare environments where they can be sprayed regularly with disinfectant without worry, while meeting the revised stringent security requirements of HIPAA and other healthcare related government security mandates. In particular, the recently announced transition to an electronic patient record from paper records necessitates a higher level of protection that only biometric security can provide.

This addition also complements the recently announced Verifi P6000, which is intended toward government deployments. This unit is a certified single fingerprint reader that meets the FIPS 201/PIV requirements of Homeland Security Presidential Directive 12 (HSPD 12). As such, the Verifi P6000 is a great match for protecting government desktops and networks everywhere. The Verifi P6000 is designed to facilitate government and enterprise logical access -- the protection of personal computers and electronic data to help prevent the inside



threat. Further, with its state of the art capacitive sensor technology it is able to capture high quality fingerprints from a wide spectrum of traditionally difficult fingers such as those with dry, moist, scarred and aged skin.

#### About Advanced Biometric Controls

Advanced Biometric Controls is a privately-held, software development company specializing in biometrics. The company develops open architecture, biometric software and applications to enable biometric technologies to interoperate in heterogeneous environments.

Advanced Biometric Controls' BiObex™ ([www.biobex.com](http://www.biobex.com)) is a flexible, netcentric system for enrolling, managing and applying biometric verification to security and identification needs. The company has several reseller partners and strategic alliances with companies throughout the United States and international representation in 17 countries internationally to assist with sales, services and strategic planning outside the United States.

#### About Zvetco Biometrics

Zvetco Biometrics is a manufacturer of best-in-class identity authentication hardware and provider of identity management solutions. Founded in 1999, Zvetco provides its customers in corporate enterprise, government, financial services, healthcare, gaming, food services and point-of-sale with cost-effective network security tools that prevent identity theft, increase accountability and eliminate the cost and inconvenience of password-based access. Zvetco Biometrics' Verifi™ line of biometric products incorporates precision fingerprint-sensing technology into ergonomic computer peripherals that deliver unparalleled performance, reliability and convenience. Available in multiple form factors, Verifi™ products use proven AuthenTec and UPEK sensor technology, offer a rugged, elegant design, a standard USB interface, enhanced security and convenience, private labeling and other custom options. Information about Zvetco and its products is available at [www.zvetcobiometrics.com](http://www.zvetcobiometrics.com) or by calling (407) 681-0111.

Verifi™ is a trademark of Zvetco Biometrics. All other trademarks, registered trademarks and service marks are the property of their respective owners.

BiObex™ is a trademark of Advanced Biometric Controls, LLC. All other trademarks, registered trademarks and service marks are the property of their respective owners.

Media Contact: Christy Elliott, Zvetco Media Director

Phone: (407) 681-0111 Extension: 804

Web site: [www.zvetcobiometrics.com](http://www.zvetcobiometrics.com)

###



### **Contact Information**

**John Russell**

Zvetco Biometrics

<http://www.zvetcobiometrics.com>

407-681-0111

### **Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **The MedZilla Report: May 2009 Employment Outlook for Biotech/Pharma/Health**

*Health care employment rebounded in May, with 24,000 new jobs created even amid widespread announcements of layoffs. Pharmaceutical companies, though, laid off fewer employees in May than in any previous month of 2009.*

Seattle, WA (Vocus) June 24, 2009 -- Health care employment saw May as something of a rebound month, with 24,000 new jobs created in the industry -- 7,000 more than in April. Average monthly job growth has remained steady in 2009. However, heavy layoffs also struck health care, with several companies announcing as many as 500 positions eliminated. Pharmaceuticals, conversely, announced relatively few layoffs compared to the previous six months.

By far the largest layoff in May was announced by Medtronic, who, according to the Associated Press, faced a 69 percent drop in profits after fourth quarter 2008. Minnesota-based health systems continued feeling the pinch, as did several facilities across New England. New Jersey's Horizon Blue Cross Blue Shield said a combination of factors including employers cutting the benefits they offer employees, which in turn affects the amount of money coming in to the insurer (The Star-Ledger, May 5, 2009). Most job elimination announcements came as a result of the downward trend in the United States economy, which has yet to turn around.

Despite layoffs, employers continued posting jobs on employment websites. New Jersey and Massachusetts both had substantial increases in the number of jobs posted -- 2.5 and 3.5 percent, respectively -- and no state saw a drop of more than one percent. The real change in postings came as a result of what types of jobs were posted; business development jobs, including research, were posted about 10 percent more overall than in April, while sales, marketing, and management positions all declined by an average of four percent. Meanwhile, employers actively searching for qualified applicants increased their efforts quite substantially in Illinois -- an increase of more than seven percent -- and New Jersey and Connecticut employers were up about three percent. California, Texas, and New York-based employers, conversely, decreased their candidate search efforts by three percent or more. Companies appeared to prefer active search to passive posting, increasing their efforts to find qualified medical, technical, and management candidates.

Job search efforts remained almost flat, changing very little from April to May. No state had swings of more than one percent. "Sometimes, the numbers can be a little deceiving," said Michele Hopps, director of marketing for MedZilla.com, the internet's leading source for health care, pharmaceutical, and biotechnology jobs. "'Change' indicates more or fewer people looking, when it's more likely that the volume, rather than the proportion, has changed." Given the sweeping layoffs being announced by health care systems nationwide, as well as in Canada, it would be surprising to learn that more people are not looking for jobs.

As it becomes more difficult to secure available jobs, it has become more important than ever for applicants to ensure that they don't sabotage themselves in preventable ways. Generally this can be avoided by securing letters of recommendation -- and, if their careers are in sales, items for the brag book -- before departing the office that



last time, but it goes beyond that. Recent news from Bozeman, Mont., indicates that employers of all types are starting to catch on to the information they can learn from social networks and the potential for exposure as a result. According to MontanasNewsStation.com, someone seeking a job with the city was asked to provide not only links to social networking sites but the usernames and passwords used to enter them. While the consensus was that asking for usernames and passwords was going too far, employers have increased their diligence in digging up digital dirt on applicants. "Once something is on the internet, it's there forever, even if you think you deleted it," said Hopps. "It's hard to keep social networks professional -- especially when you use them to share photos and news with your friends -- but mistakes, especially now, can be very costly."

About MedZilla.com:

Established in mid-1994, MedZilla is the original web site to serve career and hiring needs for professionals and employers in biotechnology, pharmaceuticals, medicine, science and healthcare. The MedZilla jobs database contains about 7,500 open positions. The resume database currently contains over 285,000 resumes with 16,800 less than three months old. These resources have been characterized as the largest, most comprehensive databases of their kind on the web in the industries served.

Medzilla® is a Registered Trademark owned by Medzilla Inc. Copyright ©2009, MedZilla, Inc. Permission is granted to reproduce and distribute this text in its entirety, and if electronically, with a link to the URL [www.medzilla.com](http://www.medzilla.com). For permission to quote from or reproduce any portion of this message, please contact Michele Hopps, Director of Marketing and Development, MedZilla, Inc. Email: [press\(at\)medzilla.com](mailto:press(at)medzilla.com).

###



### **Contact Information**

**Michele Hopps**

MedZilla, Inc.

<http://www.medzilla.com>

360-657-5681

### **Online Web 2.0 Version**

You can read the online version of this press release [here](#).



## **PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group**

*PharmaVentures Ltd, announced today that it provided the Helsinn Group with the transaction advisory support for the successful sale of Helsinn Chemicals Ireland Ltd to the Medinco C.F.M. Group, which was announced on Monday. Full details of this transaction can be found at <http://www.prnewswire.co.uk/cgi/news/release?id=259822>.*

Oxford, UK (PRWEB) June 24, 2009 -- PharmaVentures Ltd, announced today that it provided the Helsinn Group with the transaction advisory support for the successful sale of Helsinn Chemicals Ireland Ltd to the Medinco C.F.M. Group, which was announced on Monday. Full details of this transaction can be found at <http://www.prnewswire.co.uk/cgi/news/release?id=259822> .

Dr Fintan Walton, CEO, PharmaVentures commented, "PharmaVentures are delighted to have supported Helsinn in the strategic divestment of its pharmaceutical API manufacturing business. This success was achieved despite the current difficult economic environment and demonstrates why we are recognised as leaders in deal making. It also helps ensure an ongoing future for the Helsinn Chemicals Ireland business and its employees under the new ownership of the Medinco C.F.M. Group."

Please contact:

Dr Fintan Walton, CEO  
PharmaVentures Ltd  
+44 (0) 1865 784 187

About PharmaVentures Ltd

PharmaVentures ([www.pharmaventures.com](http://www.pharmaventures.com)) assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company's core business is the provision of tailored advisory and transaction services to the Life Science industry, with additional deal making support provided through the PharmaDeals® range of intelligence products which include analysis tools and reports. An innovative business, PharmaVentures additionally provides industry insight, business reviews and deal making trends through the world's first online pharmaceutical television show [www.pharmatelevision.com](http://www.pharmatelevision.com). Now in its 16th year PharmaVentures is based in Oxford, UK, employs over 50 people mostly educated to PhD or above, and has increased its turnover five fold with 80% of revenues from outside the UK. With offices in the USA and Australia, the Company works for a variety of clients from start-ups to global corporate pharmaceutical companies.

For further information about PharmaVentures Ltd please contact:

Lisa Holloway  
Marketing  
+44 (0) 1865 784 177



###

**Contact Information****Fintan Walton**

PharmaVentures Ltd

<http://www.pharmaventures.com>

01865 784 177

**Online Web 2.0 Version**You can read the online version of this press release [here](#).



## **MasterControl and Datafarm Launch GxP2eCTD at the DIA 45th Annual Meeting**

*MasterControl Inc., a global provider of GxP process and document management software solutions for life science companies, and Datafarm Inc., a world leading provider of high performance electronic regulatory submission solutions for the life sciences industry, today announced the launch of GxP2eCTD at the Drug Information Association (DIA) 45th Annual Meeting. GxP2eCTD is a bundled solution of MasterControl document management and Datafarm's S-Cubed® eCTD offering small and mid-sized life sciences companies the ability to implement a complete solution for the eCTD submission lifecycle.*

San Diego, CA (PRWEB) June 23, 2009 -- [MasterControl Inc.](#), a global provider of GxP process and document management software solutions for life science companies, and [Datafarm Inc.](#), a world leading provider of high performance electronic regulatory submission solutions for the life sciences industry, today announced the launch of GxP2eCTD at the [Drug Information Association \(DIA\)](#) 45th Annual Meeting. The companies will jointly host a launch party to be held on Tuesday, June 23rd, 2009 at Buster's Beach House at 807 West Harbor Drive (Seaport Village) in San Diego, CA. The venue is just a short walk from the San Diego Convention Center, the location of this year's DIA Annual Meeting. To register visit [the registration page](#).

GxP2eCTD allows users to readily locate, work with, and add documents directly from MasterControl's secure document repository to the eCTD submission in Datafarm's [S-Cubed®](#) solution while maintaining the full integrity and compliance of submissions. The seamless integration of MasterControl with the proven S-Cubed® eCTD solution provides a secure repository for the submissions document before, during and after submission publishing. Furthermore, the MasterControl Submissions Locker™ can provide control of the submission after publication within MasterControl just as the source documents used in the submission.

Michael Bothe, Vice President of Business Development at MasterControl, said, "It is exciting to have the ability to offer joint customers of MasterControl and Datafarm a seamless offering. We have tailored GxP2eCTD to meet the needs of small to mid-sized life sciences companies that want to simultaneously implement a complete document management and eSubmissions solution."

MasterControl's electronic document management and control solutions and [Datafarm's eSubmissions software](#) both have proven track records of maintaining integrity in electronic submission processes. By integrating the two powerful solutions, users can connect to MasterControl from Datafarm's S-Cubed eCTD without compromising the security or reliability of submissions documents. Using Datafarm's [S-Cubed eCTD submission templates](#) and the MasterControl collaboration tool users are able to create submission-ready documents from the beginning of the process while also ensuring that submissions documents are controlled, tracked, and stored in a secure electronic platform.

"Life sciences companies can take advantage of leading and proven technology at an excellent price point suited for smaller companies," said George Waidell, Vice President of Product Strategy at Datafarm. "We are looking



forward to showing off the solution at the DIA Annual Meeting."

Attendees of the DIA 45th Annual Meeting interested in seeing a GxP2eCTD demo can stop by the Datafarm booth #1900/1902.

#### About MasterControl Inc.

MasterControl produces software solutions that enable regulated companies to get their products to market faster, while reducing overall costs and increasing internal efficiency. MasterControl securely manages a company's critical information throughout the entire product lifecycle. MasterControl software is known for being easy to implement, easy to validate and easy to use. MasterControl solutions include document management, training management, quality management, product lifecycle management, audit management, bill of materials, supplier management, submissions management, and more. Supported by a comprehensive array of services based on industry best practices, MasterControl provides our customers with a complete information management solution across the entire enterprise.

For more information, visit the MasterControl website, or call 800-825-9117.

#### About Datafarm Inc.

Established in 1997, Datafarm is a world leader in high performance electronic regulatory submission solutions for the life sciences industry. Datafarm's open, modular technologies and [professional services](#) experts enable life sciences companies to meet the strict standards of regulatory authorities across the world, helping them achieve quality, accuracy, and compliance to efficiently deliver [regulatory reports and submissions](#).

Datafarm has helped hundreds of sponsor companies compress the regulatory submissions approval process, improving speed to market, cost control and productivity in order to achieve their ultimate goal of ensuring patients' and physicians' timely access to new drugs.

As a total solutions provider, Datafarm employs some of the industry's pioneers in document-based software development as well as world renowned life sciences regulatory specialists who proactively work with customers and business partners to drive new initiatives and maintain a market lead approach to development and services. Headquartered in Marlborough, Massachusetts, US, Datafarm has regional offices in California in the US, UK, France, and India. For more information visit the company website.

Datafarm and S-Cubed are registered trademarks of Datafarm Inc. All other product and company names mentioned herein are trademarks of their respective holders.

###



### Contact Information

**Kathleen Tremblay**

Datafarm Inc.

<http://www.datafarminc.com>

267-255-4142

### Online Web 2.0 Version

You can read the online version of this press release [here](#).

### News Image

